Cysteine-engineered antibody conjugate

The lack of tolerance in the prior art is solved by covalently attaching the cytotoxic agent to the cysteine ​​residue of the antibody, especially at the heavy chain position 442, forming a site-specific antibody-cytotoxic agent conjugate. The problem of achieving higher treatment index and efficacy.

CN113769108BActive Publication Date: 2024-11-08IMMUNOGEN INC
View PDF 23 Cites 0 Cited by

Patent Information

Application Number
CN202111168673.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2016-05-18
Filing Date
2016-06-28
Publication Date
2024-11-08
Estimated Expiration
2036-06-28

AI Technical Summary

Technical Problem

Existing antibody-cytotoxic agent conjugates have tolerance problems in the treatment of cancer, resulting in a low therapeutic index and it is difficult to effectively increase the ratio of maximum tolerated dose to minimum effective dose.

Method used

By covalently attaching the cytotoxic agent to the cysteine ​​residue of the antibody, especially at position 442 of the heavy chain, the site-specific antibody-cytotoxic agent conjugates are improved and the tolerance is improved Treatment index.

Benefits of technology

Compared with lysine-linked conjugates, cysteine-linked conjugates exhibit a higher therapeutic index, improving the tolerance and therapeutic efficacy of the antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003291451280000021
    Figure BDA0003291451280000021
  • Figure BDA0003291451280000023
    Figure BDA0003291451280000023
  • Figure BDA0003291451280000033
    Figure BDA0003291451280000033
Patent Text Reader

Abstract

The present invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent via an engineered Cys, such as an engineered Cys at EU / OU numbering position 442 (or C442) in the heavy chain CH3 domain corresponding to the antibody CBA. The present invention also provides a method for preparing the conjugate of the present invention. The present invention further provides compositions and methods suitable for inhibiting abnormal cell growth or treating proliferative disorders in mammals using the conjugate of the present invention.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a patent application with an application date of June 28, 2016, application number 201680038492.0, and name “Binding compound of cysteine ​​engineered antibody”.

[0002] References to related applications

[0003] This application claims the benefit of 35 USC §119(e) to U.S. Provisional Application No. 62 / 186,254, filed on June 29, 2015, and U.S. Provisional Application No. 62 / 338,245, filed on May 18, 2016, as of the filing date. The entire contents of each of the above-referenced applications are incorporated herein by reference. Field of the Invention

[0004] The present invention generally relates to conjugates of cysteine ​​engineered antibodies. The present invention also relates to methods of using such conjugates to treat diseases such as cancer. Background of the Invention

[0005] Antibody-cytotoxic agent conjugates (or "antibody-drug conjugates (ADCs)") and cell-binding agent-drug conjugates are an emerging class of powerful anti-tumor agents with efficacy against a range of cancers. Cell-binding agent-drug conjugates (such as ADCs) are typically composed of three different elements: a cell-binding agent (e.g., an antibody); a linker; and a cytotoxic moiety. Conventionally, the cytotoxic drug moiety is covalently attached to a lysine on the antibody, resulting in a heterogeneous mixture of ADCs carrying different numbers of drugs attached at different positions on the antibody molecule. SUMMARY OF THE INVENTION

[0006] The present invention provides site-specific antibody-cytotoxic agent conjugates, wherein the cytotoxic agent is covalently attached to one or more cysteine ​​residues on the antibody. Specifically, the cysteine ​​residue is located at position 442 of the heavy chain according to EU / OU numbering. The site-specific antibody-cytotoxic agent conjugates of the present invention have unexpectedly improved tolerance while maintaining similar potency, thereby producing a higher therapeutic index (ratio of maximum tolerated dose to minimum effective dose) compared to lysine-linked conjugates (Abstract #645, AACR Annual Meeting, April 18-22, 2015).

[0007] Thus, one aspect of the present invention provides an antibody-cytotoxic agent conjugate represented by the following formula:

[0008]

[0009] or a pharmaceutically acceptable salt thereof, wherein:

[0010] Ab is an antibody having a cysteine ​​residue at position 442 (EU / OU numbering) of the heavy chain of the antibody, and the cysteine ​​residue is cleaved via the thiol group S 442 Covalently linked to the linker J CB ';

[0011] D is a cytotoxic agent covalently linked to a linker L, which is covalently linked to J CB ';and

[0012] w is 1 or 2.

[0013] In certain embodiments, w is 2. Alternatively, w is 1.

[0014] In certain embodiments, the cysteine ​​residue at position 442 is recombinantly introduced into the Ab.

[0015] In certain embodiments, J CB 'for in

[0016] s1 is a site for covalent attachment to a cysteine ​​residue, and s2 is a site for covalent attachment to a group L; and

[0017] R a , R b , R c and R e is independently H or optionally substituted alkyl at each occurrence, preferably, R a , R b , R c and R e Each is H.

[0018] In certain embodiments, J CB 'for

[0019] In certain embodiments, -L- is represented by the following structural formula:

[0020]

[0021] in:

[0022] S3 is covalently linked to J CB ', and s4 is a site covalently linked to D;

[0023] E is -(CR 10 R 11 ) q -, cycloalkyl or cycloalkylalkyl;

[0024] Z does not exist, is -SO2NR9-, -NR9SO2-, -C(=O)-NR9-, -NR9-C(=O)-, -C(=O)-O-, -OC(=O)-, -C(=O)-NR9-(CH2CH2O) p -、-NR9-C(=O)-(CH2CH2O) p -、-(OCH2CH2) p -C(=O)NR9- or -(OCH2CH2) p -NR9-C(=O)-;

[0025] p is an integer from 1 to 24;

[0026] Q is H, a charged substituent or an ionizable group;

[0027] R9, R 10 , R 11 , R 12 and R 13 is independently at each occurrence H or optionally substituted alkyl; and

[0028] q and r are independently integers between 0 and 10 at each occurrence.

[0029] In certain embodiments, E is -(CR 10 R 11 ) q -.

[0030] In certain embodiments, E is

[0031] In certain embodiments, Z is -C(=O)-NR9- or -NR9-C(=O)-; in certain embodiments, R9 is -H.

[0032] In certain embodiments, Q is:

[0033] i) H;

[0034] ii)-SO3H, -Z'-SO3H, -OPO3H2, -Z'-OPO3H2, -PO3H2, -Z'-PO3H2, -CO2H, -Z'-CO2H, -NR 11 R 12 or -Z'-NR 14 R 15 or a pharmaceutically acceptable salt thereof; or

[0035] iii)-N + R 14 R 15 R 16 X-or-Z'-N +R 14 R 15 R 16 X - ;

[0036] Z' is an optionally substituted alkylene group, an optionally substituted cycloalkylene group or an optionally substituted phenylene group; preferably, Z' is an optionally substituted alkylene group;

[0037] R 14 , R 15 and R 16 are each independently optionally substituted alkyl; and

[0038] X - It is a pharmaceutically acceptable anion.

[0039] In certain embodiments, Q is H or -SO3M, wherein M is H + 、Na + or K + .

[0040] In certain embodiments, R9, R 10 , R 11 , R 12 and R 13 are all H; and q and r are each independently an integer between 1 and 6.

[0041] In certain embodiments, -J CB '-L- is represented by any of the following structural formulas:

[0042] as well as

[0043] Where M is H + or a pharmaceutically acceptable cation.

[0044] In certain embodiments, -L- is represented by the following structural formula:

[0045]

[0046] in:

[0047] S3 is covalently linked to J CB ', and s4 is a site covalently linked to D;

[0048] R 19 To R 22 is independently at each occurrence H or optionally substituted alkyl;

[0049] m and n are each independently an integer between 0 and 10;

[0050] Rh is H or optionally substituted alkyl;

[0051] P is an optionally substituted alkylene group, -(CH2-CH2-O) j - (wherein the oxygen atom is linked to a -(C=O)- group, which is linked to P), an amino acid residue, or a peptide containing 2 to 20 amino acid residues; and

[0052] j is an integer from 1 to 24.

[0053] In certain embodiments, R 19 , R 20 , R 21 and R 22 Each is H; and m and n are each independently an integer between 1 and 6.

[0054] In certain embodiments, P is an amino acid residue or a peptide containing 2 to 10 amino acid residues; preferably, P is a peptide containing 2 to 5 amino acid residues.

[0055] In certain embodiments, each amino acid residue is the residue of an amino acid independently selected from a naturally occurring amino acid, a synthetic amino acid, an amino acid analog, and an amino acid mimetic that functions in a manner similar to the naturally occurring amino acids.

[0056] In certain embodiments, each amino acid residue is a residue of an amino acid independently selected from the group consisting of histidine, alanine, isoleucine, arginine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, glycine, valine, proline, serine, tyrosine, N-methyl-histidine, N-methyl-alanine, N-methyl-isoleucine, N-methyl-arginine, N-methyl-leucine, N-methyl-asparagine, N-methyl-lysine, N-methyl-aspartic acid, N-methyl-methionine, N-methyl-cysteine, N-methyl-phenylalanine, N-methyl-glutamic acid, N-methyl-threonine, Preferably, each amino acid residue is an independently selected residue of glycine or alanine.

[0057] In certain embodiments, P is a peptide cleavable by a protease.

[0058] In certain embodiments, P is selected from the group consisting of Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Trp, Cit, Phe-Ala, Phe-N 9 -Tosyl-Arg, Phe-N 9- Nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala-Leu (SEQ ID NO: 14), β-Ala-Leu-Ala-Leu (SEQ ID NO: 15), Gly-Phe-Leu-Gly (SEQ ID NO: 16), Val-Arg, Arg-Val, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-A la, Ala-D-Ala, D-Ala-Ala and D-Ala-D-Ala, Gly-Gly-Gly, Ala-Ala-Ala, D-Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala-D-Ala, Ala-Val-Cit, Ala-Val-Ala and β-Ala-Gly-Gly-Gly. For example, P can be Gly-Gly-Gly, Ala-Ala-Ala, D-Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Val-Ala, or β-Ala-Gly-Gly-Gly.

[0059] In certain embodiments, -J CB '-L- is represented by the following structural formula:

[0060]

[0061] In certain embodiments, -L- is represented by the following structural formula:

[0062]

[0063] in:

[0064] S3 is covalently linked to J CB ', and s4 is a site covalently linked to D;

[0065] R 23 and R 24 is independently at each occurrence H or optionally substituted alkyl;

[0066] m' is an integer between 0 and 10; and

[0067] R h’ is H or optionally substituted alkyl.

[0068] In certain embodiments, R 23 With R 24 are all H; and m' is an integer between 1 and 6.

[0069] In certain embodiments, R h 'For H.

[0070] In certain embodiments, -J CB '-L- is represented by the following structural formula:

[0071]

[0072] In certain embodiments, D is a benzodiazepine compound, such as an indolinobenzodiazepine compound.

[0073] In certain embodiments, D is represented by the following structural formula:

[0074]

[0075]

[0076] or a pharmaceutically acceptable salt thereof, wherein:

[0077] Double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is selected from -H or an amine protecting group; and Y is selected from -OR, -OCOR', -SR, -NR'R", -SO3M, -SO2M or -OSO3M, wherein M is -H or a cation;

[0078] R is -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or a PEG group -(CH2CH2O) n -R c , wherein n is an integer from 1 to 24, and R c is a straight or branched chain alkyl group having 1 to 4 carbon atoms;

[0079] R' and R" are each independently selected from -H, -OH, -OR, -NRR g’ , -COR, an optionally substituted linear, branched or cyclic alkyl group having 1 to 10 carbon atoms, an optionally substituted aryl group having 6 to 18 carbon atoms, an optionally substituted 3 to 18-membered heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N and P, a PEG group -(CH2CH2O) n -R c , and R g’is -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or a PEG group -(CH2CH2O) n -R c ;

[0080] X' is selected from the group consisting of: -H, -OH, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a phenyl group, and an amine protecting group;

[0081] Y' is selected from the group consisting of: -H, an oxo group (i.e., Y' together with the carbon atom to which it is attached forms a -C(=O)- group), a substituted or unsubstituted straight chain, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0082] A and A' are selected from -O- and -S-;

[0083] W' is absent or selected from -O-, -N(R e )-、-N(R e )-C(=O)-, -N(C(=O)R e )-、-S- or -CH2-S-、-CH2NR e -;

[0084] R x Absent or selected from linear, branched or cyclic alkyl groups having 1 to 10 carbon atoms;

[0085] R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or -(CH2-CH2-O) n -R k , where R k is -H, a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, optionally carrying a secondary amino group (e.g., -NHR 101 ) or tertiary amino group (-NR 101 R 102 ) or a 5- or 6-membered nitrogen-containing heterocyclic ring, wherein R 101 and R 102 Each is independently a straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0086] G is selected from -CH- or -N-; and

[0087] R6 is -H, -R, -OR, -SR, -NR'R", -NO2 or halogen.

[0088] In certain embodiments, D is represented by the following structural formula:

[0089]

[0090] In certain embodiments:

[0091] Double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -OH or -SO3M;

[0092] M is -H or a pharmaceutically acceptable cation;

[0093] X' and Y' are both -H;

[0094] A and A' are both -O-;

[0095] R6 is -OMe; and

[0096] R x is a straight chain or branched chain alkyl group having 1 to 6 carbon atoms.

[0097] In certain embodiments, D is represented by the following structural formula:

[0098]

[0099]

[0100] or a pharmaceutically acceptable salt thereof, wherein the double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -SO3M; and M is H + or a pharmaceutically acceptable cation thereof.

[0101] In certain embodiments, Y is -SO3M, and M is H + 、Na + or K + .

[0102] In certain embodiments, D is represented by the following structural formula:

[0103]

[0104]

[0105] or a pharmaceutically acceptable salt thereof, wherein:

[0106] One of L', L", and L'' is represented by the following formula:

[0107] -Z1-P1-Z2-R x1 -C(=O)-(A'), or

[0108] -N(R e )-R x1 -C(=O)-(D′);

[0109] and the other two are each independently selected from -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c , halogen, guanidine [-NH(C=NH)NH2], -OR, -NR'R", -NO2, -NR'COR", -SR, -SOR', -SO2R', -SO3H, -OSO3H, -SO2NR'R", cyano, azido, -COR', -OCOR', and -OCONR'R";

[0110] One of Z1 and Z2 is -C(=O)-, and the other is -NR5-;

[0111] P1 is an amino acid residue or a peptide containing 2 and 20 amino acid residues;

[0112] R x1 is an optionally substituted straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0113] R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or -(CH2-CH2-O) n -R k , where R k is -H, a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, optionally carrying a secondary amino group (e.g., -NHR 101 ) or tertiary amino group (-NR 101 R 102 ) or a 5- or 6-membered nitrogen-containing heterocyclic ring, wherein R 101 and R 102 Each is independently a straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0114] Double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X1 is absent and Y1 is -H or a straight or branched chain alkyl group having 1 to 4 carbon atoms, and when it is a single bond, X1 is -H or an amine protecting moiety; and Y1 is a leaving group selected from the group consisting of -OR, -OCOR', -OCOOR', -OCONR'R", -NR'R", -NR'COR", -NR'NR'R", an optionally substituted 5- or 6-membered nitrogen-containing heterocycle, a -NR Guanidine represented by '(C=NH)NR'R", amino acid or peptide represented by -NRCOP', -SR, -SOR', halogen, cyano, azido, -OSO3H (or its salt), sulfite (-SO3H or -SO2H or its salt), metabisulfite (H2S2O5 or its salt), mono-, di-, tri- and tetra-thiophosphate (PO3SH3, PO2S2H2, POS3H2, PS4H2 or its salt), thiophosphate (R i O)2PS(OR i ), R i S-, R i SO, R i SO2、R i SO3, thiosulfate (HS2O3 or its salt), dithionite (HS2O4 or its salt), dithiophosphate (P(=S)(OR k’ )(S)(OH) or its salt), hydroxamic acid (R k’ C(=O)NOH or its salt) and formaldehyde sulfoxylate (HOCH2SO2 - or its salt) or a mixture thereof, wherein R i is a straight or branched alkyl group having 1 to 10 carbon atoms and is substituted with at least one selected from -N(R j )2, -CO2H, -SO3H and -PO3H; R 1 may be further optionally substituted with alkyl substituents as described herein; R j is a straight or branched chain alkyl group having 1 to 6 carbon atoms; R k’ is a linear, branched or cyclic alkyl, alkenyl or alkynyl, aryl, heterocyclic or heteroaryl group having 1 to 10 carbon atoms;

[0115] P' is an amino acid residue or a peptide containing 2 to 20 amino acid residues,

[0116] R is independently selected at each occurrence from the group consisting of: -H, optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, polyethylene glycol unit -(CH2CH2O) n -R c, an optionally substituted aryl group having 6 to 18 carbon atoms, an optionally substituted 5 to 18 membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, or an optionally substituted 3 to 18 membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;

[0117] R' and R" are each independently selected from -H, -OH, -OR, -NHR, -NR2, -COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c and optionally substituted 3 to 18 membered heterocyclic rings having 1 to 6 heteroatoms independently selected from O, S, N and P;

[0118] R c is -H or an optionally substituted straight or branched chain alkyl group having 1 to 4 carbon atoms;

[0119] n is an integer from 1 to 24;

[0120] X1' is selected from -H, an amine protecting group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c , optionally substituted aryl having 6 to 18 carbon atoms, optionally substituted 5 to 18 membered heteroaryl rings containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, and optionally substituted 3 to 18 membered heterocyclic rings containing 1 to 6 heteroatoms independently selected from O, S, N and P;

[0121] Y1' is selected from -H, an oxo group (i.e., Y1' together with the carbon atom to which it is attached forms a -C(=O)- group), an optionally substituted straight chain, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, an optionally substituted 6 to 18 membered aryl group, an optionally substituted 5 to 18 membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, an optionally substituted 3 to 18 membered heterocyclic ring having 1 to 6 heteroatoms;

[0122] R1, R2, R3, R4, R1', R2', R3' and R4' are each independently selected from the group consisting of: -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c , halogen, guanidine [-NH(C=NH)NH2], -OR, -NR'R", -NO2, -NCO, -NR'COR", -SR, -SOR', -SO2R', -SO3- H, -OSO3H, -SO2NR'R", cyano, azido, -COR', -OCOR', and -OCONR'R";

[0123] R6 is -H, -R, -OR, -SR, -NR'R", -NO2 or halogen;

[0124] G is -CH- or -N-;

[0125] A and A' are the same or different and are independently selected from -O-, oxo (-C(=O)-), -CRR'O-, -CRR'-, -S-, -CRR'S-, -NR5 and -CRR'N(R5)-; and

[0126] R5, at each occurrence, is independently -H or an optionally substituted straight or branched chain alkyl group having 1 to 10 carbon atoms.

[0127] In certain embodiments, D is represented by the following structural formula:

[0128]

[0129] or a pharmaceutically acceptable salt thereof.

[0130] In certain embodiments, one of L', L", and L'" is represented by formula (A') or (D'), and the rest are -H, a straight or branched chain alkyl group having 1 to 6 carbon atoms, halogen, -OH, (C1-C6) alkoxy, or -NO2.

[0131] In certain embodiments, L' is represented by formula (A'); and L" and L'" are both -H.

[0132] In certain embodiments, L' is represented by formula (D'); and L" and L'" are both -H.

[0133] In certain embodiments, R x1 It is a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms or a charged substituent or ionizable group Q which is optionally substituted with halogen, -OH, -SO3H, (C1-C3)alkyl, (C1-C3)alkoxy, or halo(C1-C3)alkyl.

[0134] In certain embodiments, L' is represented by the formula:

[0135] -NR5-P1-C(=O)-(CR a R b ) s -C(=O)-(B1′);

[0136] -NR5-P1-C(=O)-Cy-(CR a R b ) s1’ -C(=O)-(B2');

[0137] -C(=O)-P1-NR5-(CR a R b ) s -C(=O)-(C1′), or

[0138] -C(=O)-P1-NR5-Cy-(CR a R b ) s1’ -C(=O)-(C2')

[0139] in:

[0140] R a and R b Each occurrence is independently -H, (C1-C3)alkyl, or a charged substituent or ionizable group Q;

[0141] s is an integer from 1 to 6;

[0142] s1' is 0 or an integer from 1 to 6; and

[0143] Cy is a cyclic alkyl group having 5 or 6 ring carbon atoms which is optionally substituted with halogen, -OH, (C1-C3)alkyl, (C1-C3)alkoxy or halo(C1-C3)alkyl.

[0144] In certain embodiments, R a With R b are H; Cy in formula (B2') and (C2') is cyclohexane; and R5 is H or Me.

[0145] In certain embodiments, s1′ is 0 or 1.

[0146] In certain embodiments, the charged substituent or ionizable group Q is i) -SO3H, -Z'-SO3H, -OPO3H2, -Z'-OPO3H2, -PO3H2, -Z'-PO3H2, -CO2H, -Z'-CO2H, -NR 11 R 12 or -Z'-NR 11 R 12 or a pharmaceutically acceptable salt thereof; or ii) -N + R 14 R 15 R 16 X - or -Z'-N + R14 R 15 R 16 X - ; Z' is an optionally substituted alkylene group, an optionally substituted cycloalkylene group or an optionally substituted phenylene group; R 14 To R 16 are each independently optionally substituted alkyl; and X - It is a pharmaceutically acceptable anion.

[0147] In certain embodiments, Q is -SO3H or a pharmaceutically acceptable salt thereof.

[0148] In certain embodiments, P1 is a peptide containing 2 to 10 amino acid residues. For example, P1 can be a peptide containing 2 to 5 amino acid residues, such as Gly-Gly-Gly, Ala-Val, Val-Ala, Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Trp, Cit, Phe-Ala, Phe-N 9 -Tosyl-Arg, Phe-N 9 -Nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala-Leu, β-Ala-Leu-Ala-Leu, Gly-Phe-Leu-Gly, Val-Arg, Arg-Val, Arg-Arg, Val- In some embodiments, P1 is Gly-Gly-Gly, Ala-Val, Ala-Ala, Ala-D-Ala, D-Ala-Ala, or D-Ala-D-Ala.

[0149] In certain embodiments, the double line between N and C Represents a double bond.

[0150] In certain embodiments, the double line between N and C represents a single bond, X1 is -H or an amine protecting group; and Y1 is selected from -OR, -OCOR', -SR, -NR'R", an optionally substituted 5- or 6-membered nitrogen-containing heterocycle, -SO3M, -SO2M and -OSO3M, wherein M is H + or a pharmaceutically acceptable cation.

[0151] In certain embodiments, Y1 is selected from -SO3M, -OH, -OMe, -OEt, or -NHOH.

[0152] In certain embodiments, Y1 is -SO3M or -OH, wherein M is H + 、Na + or K + .

[0153] In certain embodiments, X1' is selected from the group consisting of -H, -OH, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, and phenyl.

[0154] In certain embodiments, X1' is -H, -OH, (C1-C3) alkyl, halo (C1-C3) alkyl or phenyl. Preferably, X1' is -H, -OH or -Me. In certain embodiments, X1' is -H.

[0155] In certain embodiments, Y1' is selected from the group consisting of: -H, oxo, an optionally substituted straight chain, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms. In certain embodiments, Y1' is -H, oxo, (C1-C3) alkyl or halo (C1-C3) alkyl. In certain embodiments, Y1' is -H or oxo. In certain embodiments, Y1' is -H.

[0156] In certain embodiments, A and A' are the same or different and are selected from -O-, -S-, -NR5- and oxo-(C=O)-. In certain embodiments, A and A' are the same or different and are selected from -O- and -S-. In certain embodiments, A and A' are -O-.

[0157] In certain embodiments, R6 is -OMe.

[0158] In certain embodiments, R1, R2, R3, R4, R1', R2', R3' and R4' are independently -H, halogen, -NO2, -OH, (C1-C3) alkyl, halo (C1-C3) alkyl or (C1-C3) alkoxy. In certain embodiments, R1, R2, R3, R4, R1', R2', R3' and R4' are all -H.

[0159] In certain embodiments, R, R', R", and R5 are each independently -H or (C1-C3)alkyl.

[0160] In certain embodiments:

[0161] Double line between N and C represents a single bond or a double bond, with the restriction that when it is a double bond, X1 is absent and Y1 is -H; and when it is a single bond, X1 is -H and Y1 is -OH or -SO3M;

[0162] R1, R2, R3, R4, R1', R2', R3' and R4' are all -H;

[0163] R6 is -OMe;

[0164] X1' and Y1' are both -H;

[0165] A and A' are -O-; and

[0166] M is H + 、Na + or K + .

[0167] In certain embodiments, D is represented by the following structural formula:

[0168]

[0169]

[0170]

[0171] The double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -SO3M; and M is H + or a pharmaceutically acceptable cation thereof; M is H + or a pharmaceutically acceptable cation thereof.

[0172] In certain embodiments, the conjugate is represented by the following structural formula:

[0173]

[0174]

[0175]

[0176]

[0177]

[0178]

[0179] or a pharmaceutically acceptable salt thereof, wherein the double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -SO3M; and M is H + or a pharmaceutically acceptable cation thereof.

[0180] In certain embodiments, when present, M is H + 、Na + or K + .

[0181] Another aspect of the present invention provides a compound represented by the following structural formula:

[0182] DLJ CB ,

[0183] or a pharmaceutically acceptable salt thereof, wherein:

[0184] D is represented by the following structural formula:

[0185]

[0186]

[0187] or a pharmaceutically acceptable salt thereof, wherein:

[0188] Double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is selected from -H or an amine protecting group; and Y is selected from -OR, -OCOR', -SR, -NR'R", -SO3M, -SO2M or -OSO3M, wherein M is -H or a cation;

[0189] R is -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or a PEG group -(CH2CH2O) n -R c , wherein n is an integer from 1 to 24, and R c is a straight or branched chain alkyl group having 1 to 4 carbon atoms;

[0190] R' and R" are each independently selected from -H, -OH, -OR, -NRR g’, -COR, an optionally substituted linear, branched or cyclic alkyl group having 1 to 10 carbon atoms, an optionally substituted aryl group having 6 to 18 carbon atoms, an optionally substituted 3 to 18-membered heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N and P, a PEG group -(CH2CH2O) n -R c , and R g’ is -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or a PEG group -(CH2CH2O) n -R c ;

[0191] X' is selected from the group consisting of: -H, -OH, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a phenyl group, and an amine protecting group;

[0192] Y' is selected from the group consisting of: -H, an oxo group, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0193] A and A' are selected from -O- and -S-;

[0194] W' is absent or selected from -O-, -N(R e )-、-N(R e )-C(=O)-, -N(C(=O)R e )-、-S- or -CH2-S-、-CH2NR e -;

[0195] R x Absent or selected from linear, branched or cyclic alkyl groups having 1 to 10 carbon atoms;

[0196] R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or -(CH2-CH2-O) n -R k , where R k is -H, a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, optionally carrying a secondary amino group (e.g., -NHR 101 ) or tertiary amino group (-NR 101 R 102 ) or a 5- or 6-membered nitrogen-containing heterocyclic ring, wherein R 101 and R 102 Each is independently a straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0197] G is selected from -CH- or -N-;

[0198] R6 is -H, -R, -OR, -SR, -NR'R", -NO2 or halogen;

[0199] -L- is represented by the following structural formula:

[0200]

[0201] in:

[0202] S3 is covalently linked to J CB , and s4 is a site covalently linked to D;

[0203] E is -(CR 10 R 11 ) q -, cycloalkyl or cycloalkylalkyl;

[0204] Z does not exist, is -SO2NR9-, -NR9SO2-, -C(=O)-NR9-, -NR9-C(=O)-, -C(=O)-O-, -OC(=O)-, -C(=O)-NR9-(CH2CH2O) p -、-NR9-C(=O)-(CH2CH2O) p -、-(OCH2CH2) p -C(=O)NR9- or -(OCH2CH2) p -NR9-C(=O)-;

[0205] p is an integer from 1 to 1000;

[0206] Q is H, a charged substituent or an ionizable group;

[0207] R9, R 10 , R 11 , R 12 and R 13 is independently at each occurrence H or optionally substituted alkyl;

[0208] q and r, at each occurrence, are independently integers between 0 and 10; and

[0209] J CB for X'-CR b R c -C(=O)-, X'-CR b R c -C(=O)-NR e -、

[0210] In certain embodiments, D is represented by the following structural formula:

[0211]

[0212] or a pharmaceutically acceptable salt thereof.

[0213] In certain embodiments, R a , R b , R c and R e Each is H.

[0214] In certain embodiments, J CB for

[0215] In certain embodiments:

[0216] Double line between N and C represents a single bond or a double bond, with the restriction that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H; Y is -OH or -So3M;

[0217] M is -H or a pharmaceutically acceptable cation (e.g., Na + );

[0218] X' and Y' are both -H;

[0219] A and A' are both -O-;

[0220] R6 is -OMe; and

[0221] R x is a straight chain or branched chain alkyl group having 1 to 6 carbon atoms.

[0222] In certain embodiments, D is represented by the following structural formula:

[0223]

[0224]

[0225] or a pharmaceutically acceptable salt thereof.

[0226] In certain embodiments, Y is -SO3M; and M is H + 、Na + or K + .

[0227] In certain embodiments, E is -(CR 10 R 11 ) q -.

[0228] In certain embodiments, E is

[0229] In certain embodiments, Z is -C(=O)-NR9- or -NR9-C(=O)-. In certain embodiments, R9 is -H.

[0230] In certain embodiments, Q is:

[0231] i) H;

[0232] ii)-SO3H, -Z'-SO3H, -OPO3H2, -Z'-OPO3H2, -PO3H2, -Z'-PO3H2, -CO2H, -Z'-CO2H, -NR 11 R 12 or -Z'-NR 14 R 15 or a pharmaceutically acceptable salt thereof; or

[0233] iii)-N + R 14 R 15 R 16 X-or-Z'-N + R 14 R 15 R 16 X - ;

[0234] Z' is optionally substituted alkylene, optionally substituted cycloalkylene or optionally substituted phenylene;

[0235] R 14 , R 15 and R 16 are each independently optionally substituted alkyl; and

[0236] X - It is a pharmaceutically acceptable anion.

[0237] In certain embodiments, Z' is optionally substituted alkylene.

[0238] In certain embodiments, Q is H or -SO3M, wherein M is H + 、Na + or K + .

[0239] In certain embodiments, R9, R 10 , R 11 , R 12 and R 13 are all H; and q and r are each independently an integer between 1 and 6.

[0240] In certain embodiments, -LJ CB Represented by the following structural formula:

[0241]

[0242]

[0243] Where M is H + or a pharmaceutically acceptable cation.

[0244] In certain embodiments, the compound is represented by the following structural formula:

[0245]

[0246]

[0247]

[0248] or a pharmaceutically acceptable salt thereof, wherein the double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -SO3M; and M is H + or a pharmaceutically acceptable cation thereof.

[0249] Another aspect of the present invention provides a compound represented by the following structural formula:

[0250] DLJ CB ,

[0251] or a pharmaceutically acceptable salt thereof, wherein:

[0252] D is represented by the following structural formula:

[0253]

[0254] or a pharmaceutically acceptable salt thereof, wherein:

[0255] One of L', L", and L'' is represented by the following formula:

[0256] -Z1-P1-Z2-R x1 -C(=O)- (A'), or

[0257] -N(R e )-R x1 -C(=O)- (D');

[0258] and the other two are each independently selected from -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c, halogen, guanidine [-NH(C=NH)NH2], -OR, -NR'R", -NO2, -NR'COR", -SR, -SOR', -SO2R', -SO3H, -OSO3H, -SO2NR'R", cyano, azido, -COR', -OCOR', and -OCONR'R";

[0259] One of Z1 and Z2 is -C(=O)-, and the other is -NR5-;

[0260] P1 is an amino acid residue or a peptide containing 2 and 20 amino acid residues;

[0261] R x1 is an optionally substituted straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0262] R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or -(CH2-CH2-O) n -R k , where R k is -H, a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, optionally carrying a secondary amino group (e.g., -NHR 101 ) or tertiary amino group (-NR 101 R 102 ) or a 5- or 6-membered nitrogen-containing heterocyclic ring, wherein R 101 and R 102 Each is independently a straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0263] Double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X1 is absent and Y1 is -H or a straight or branched chain alkyl group having 1 to 4 carbon atoms, and when it is a single bond, X1 is -H or an amine protecting moiety; and Y1 is a leaving group selected from the group consisting of -OR, -OCOR', -OCOOR', -OCONR'R", -NR'R", -NR'COR", -NR'NR'R", an optionally substituted 5- or 6-membered nitrogen-containing heterocycle, a -NR Guanidine represented by '(C=NH)NR'R", amino acid or peptide represented by -NRCOP', -SR, -SOR', halogen, cyano, azido, -OSO3H (or its salt), sulfite (-SO3H or -SO2H or its salt), metabisulfite (H2S2O5 or its salt), mono-, di-, tri- and tetra-thiophosphate (PO3SH3, PO2S2H2, POS3H2, PS4H2 or its salt), thiophosphate (R i O)2PS(OR i ), Ri S-, R i SO, R i SO2、R i SO3, thiosulfate (HS2O3 or its salt), dithionite (HS2O4 or its salt), dithiophosphate (P(=S)(OR k’ )(S)(OH) or its salt), hydroxamic acid (R k’ C(=O)NOH or its salt) and formaldehyde sulfoxylate (HOCH28O2 - or its salt) or a mixture thereof, wherein R i is a straight or branched alkyl group having 1 to 10 carbon atoms and is substituted with at least one selected from -N(R j )2, -CO2H, -SO3H and -PO3H; R i may be further optionally substituted with alkyl substituents as described herein; R j is a straight or branched chain alkyl group having 1 to 6 carbon atoms; R k’ is a linear, branched or cyclic alkyl, alkenyl or alkynyl, aryl, heterocyclic or heteroaryl group having 1 to 10 carbon atoms;

[0264] P' is an amino acid residue or a peptide containing 2 to 20 amino acid residues,

[0265] R is independently selected at each occurrence from the group consisting of: -H, optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, polyethylene glycol unit -(CH2CH2O) n -R c , an optionally substituted aryl group having 6 to 18 carbon atoms, an optionally substituted 5 to 18 membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, or an optionally substituted 3 to 18 membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;

[0266] R' and R" are each independently selected from -H, -OH, -OR, -NHR, -NR2, -COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c and optionally substituted 3 to 18 membered heterocyclic rings having 1 to 6 heteroatoms independently selected from O, S, N and P;

[0267] R c is -H or an optionally substituted straight or branched chain alkyl group having 1 to 4 carbon atoms;

[0268] n is an integer from 1 to 24;

[0269] X1' is selected from -H, an amine protecting group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c , optionally substituted aryl having 6 to 18 carbon atoms, optionally substituted 5 to 18 membered heteroaryl rings containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, and optionally substituted 3 to 18 membered heterocyclic rings containing 1 to 6 heteroatoms independently selected from O, S, N and P;

[0270] Y1' is selected from -H, oxo, optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, optionally substituted 6 to 18 membered aryl, optionally substituted 5 to 18 membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, optionally substituted 3 to 18 membered heterocyclic ring having 1 to 6 heteroatoms;

[0271] R1, R2, R3, R4, R1', R2', R3' and R4' are each independently selected from the group consisting of: -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c , halogen, guanidine [-NH(C=NH)NH2], -OR, -NR'R", -NO2, -NCO, -NR'COR", -SR, -SOR', -SO2R', -SO3 - H, -OSO3H, -SO2NR'R", cyano, azido, -COR', -OCOR', and -OCONR'R";

[0272] R6 is -H, -R, -OR, -SR, -NR'R", -NO2 or halogen;

[0273] G is -CH- or -N-;

[0274] A and A' are the same or different and are independently selected from -O-, oxo (-C(=O)-), -CRR'O-, -CRR'-, -S-, -CRR'S-, -NR5 and -CRR'N(R5)-; and

[0275] R5, at each occurrence, is independently -H or an optionally substituted straight or branched chain alkyl group having 1 to 10 carbon atoms;

[0276] -L- is represented by the following structural formula:

[0277]

[0278] in:

[0279] S3 is covalently linked to J CB ', and s4 is a site covalently linked to D;

[0280] R 23 and R 24 is independently at each occurrence H or optionally substituted alkyl;

[0281] m' is an integer between 0 and 10;

[0282] R h’ is H or optionally substituted alkyl; and

[0283] J CB for X'-CR b R c -C(=O)-, X'-CR b R c -C(=O)-NR e -、

[0284] In certain embodiments, D is represented by the following structural formula:

[0285]

[0286] or a pharmaceutically acceptable salt thereof.

[0287] In certain embodiments, R a , R b , R c and R e Each is H.

[0288] In certain embodiments, J CB for

[0289] In certain embodiments, one of L', L", and L'" is represented by formula (A') or (D'), and the rest are -H, a straight or branched chain alkyl group having 1 to 6 carbon atoms, halogen, -OH, (C1-C6) alkoxy, or -NO2.

[0290] In certain embodiments, L' is represented by formula (A'); and L" and L'" are both -H.

[0291] In certain embodiments, L' is represented by formula (D'); and L" and L'" are both -H.

[0292] In certain embodiments, R x1It is a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms or a charged substituent or ionizable group Q which is optionally substituted with halogen, -OH, -SO3H, (C1-C3)alkyl, (C1-C3)alkoxy, or halo(C1-C3)alkyl.

[0293] In certain embodiments, L' is represented by the formula:

[0294] -NR5-P1-C(=O)-(CR a R b ) s -C(=O)-(B1′);

[0295] -NR5-P1-C(=O)-Cy-(CR a R b ) s1 '-C(=O)-(B2');

[0296] -C(=O)-P1-NR5-(CR a R b ) s -C(=O)-(C1′), or

[0297] -C(=O)-P1-NR5-Cy-(CR a R b ) s1 '-C(=O)-(C2')

[0298] in:

[0299] R a and R b Each occurrence is independently -H, (C1-C3)alkyl, or a charged substituent or ionizable group Q;

[0300] s is an integer from 1 to 6;

[0301] s1' is 0 or an integer from 1 to 6; and

[0302] Cy is a cyclic alkyl group having 5 or 6 ring carbon atoms which is optionally substituted with halogen, -OH, (C1-C3)alkyl, (C1-C3)alkoxy or halo(C1-C3)alkyl.

[0303] In certain embodiments, R a With R b are H; Cy of formula (B2') and (C2') is cyclohexane; and R5 is H or Me.

[0304] In certain embodiments, s1′ is 0 or 1.

[0305] In certain embodiments, the charged substituent or ionizable group Q is i) -SO3H, -Z'-SO3H, -OPO3H2, -Z'-OPO3H2, -PO3H2, -Z'-PO3H2, -CO2H, -Z'-CO2H, -NR 11 R l2 or -Z'-NR 11 R 12 or a pharmaceutically acceptable salt thereof; or ii) -N + R 14 R 15 R 16 X - or -Z'-N + R 14 R 15 R 16 X - ; Z' is an optionally substituted alkylene group, an optionally substituted cycloalkylene group or an optionally substituted phenylene group; R 14 To R 16 are each independently optionally substituted alkyl; and X - It is a pharmaceutically acceptable anion.

[0306] In certain embodiments, Q is -SO3H or a pharmaceutically acceptable salt thereof.

[0307] In certain embodiments, P1 is a peptide containing 2 to 10 amino acid residues. For example, P1 can be a peptide containing 2 to 5 amino acid residues, such as Gly-Gly-Gly, Ala-Val, Val-Ala, Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Trp, Cit, Phe-Ala, Phe-N 9 -Tosyl-Arg, Phe-N 9- Nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala-Leu (SEQ ID NO: 14), β-Ala-Leu-Ala-Leu (SEQ ID NO: 15), Gly-Phe-Leu-Gly (SEQ ID NO: 16), Val-Arg, Arg-Val, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-D-Ala, Ala-Met and Met-Ala. In certain embodiments, P1 is Gly-Gly-Gly, Ala-Val, Ala-Ala, Ala-D-Ala, D-Ala-Ala and D-Ala-D-Ala.

[0308] In certain embodiments, the double line between N and C Represents a double bond.

[0309] In certain embodiments, the double line between N and C represents a single bond, X1 is -H or an amine protecting group; and Y1 is selected from -OR, -OCOR', -SR, -NR'R", an optionally substituted 5- or 6-membered nitrogen-containing heterocycle, -SO3M, -SO2M and -OSO3M, wherein M is H + or a pharmaceutically acceptable cation. In certain embodiments, Y1 is selected from -SO3M, -OH, -OMe, -OEt or -NHOH. In certain embodiments, Y1 is -SO3M or -OH, and M is H + 、Na + or K + .

[0310] In certain embodiments, X1' is selected from the group consisting of: -H, -OH, an optionally substituted straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, and phenyl. In certain embodiments, X1' is -H, -OH, (C1-C3) alkyl, halo (C1-C3) alkyl or phenyl. In certain embodiments, X1' is -H, -OH or -Me. In certain embodiments, X1' is -H.

[0311] In certain embodiments, Y1' is selected from the group consisting of: -H, oxo, an optionally substituted straight chain, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms. In certain embodiments, Y1' is -H, oxo, (C1-C3) alkyl or halo (C1-C3) alkyl. In certain embodiments, Y1' is -H or oxo. In certain embodiments, Y1' is -H.

[0312] In certain embodiments, A and A' are the same or different and are selected from -O-, -S-, -NR5- and oxo-(C=O)-. In certain embodiments, A and A' are the same or different and are selected from -O- and -S-. In certain embodiments, A and A' are -O-.

[0313] In certain embodiments, R6 is -OMe.

[0314] In certain embodiments, R1, R2, R3, R4, R1', R2', R3' and R4' are independently -H, halogen, -NO2, -OH, (C1-C3) alkyl, halo (C1-C3) alkyl or (C1-C3) alkoxy. In certain embodiments, R1, R2, R3, R4, R1', R2', R3' and R4' are all -H.

[0315] In certain embodiments, R, R', R", and R5 are each independently -H or (C1-C3)alkyl.

[0316] In certain embodiments:

[0317] Double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X1 is absent and Y1 is -H, and when it is a single bond, X1 is -H and Y is -OH or -So3M;

[0318] R1, R2, R3, R4, R1', R2', R3' and R4' are all -H;

[0319] R6 is -OMe;

[0320] X1' and Y1' are both -H;

[0321] A and A' are -O-; and

[0322] M is H + 、Na + or K + .

[0323] In certain embodiments, D is represented by the following structural formula:

[0324]

[0325]

[0326] or a pharmaceutically acceptable salt thereof, wherein the double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -SO3M; and M is H + or a pharmaceutically acceptable cation thereof.

[0327] In certain embodiments, M is H + 、Na + or K + .

[0328] In certain embodiments, R 23 With R 24 are H; and m' is an integer between 1 and 6. In certain embodiments, R h 'For H.

[0329] In certain embodiments, -LJ CB Represented by the following structural formula:

[0330]

[0331] In certain embodiments, the compound is represented by the following structural formula:

[0332]

[0333]

[0334] The double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -SO3M; and M is H + or a pharmaceutically acceptable cation thereof.

[0335] In certain embodiments, M is H + 、Na + or K + .

[0336] Another aspect of the present invention provides a pharmaceutical composition comprising the conjugate of the present invention and a pharmaceutically acceptable carrier.

[0337] Another aspect of the invention provides a method of inhibiting abnormal cell growth or treating a proliferative disorder, an autoimmune disorder, a destructive bone disorder, an infectious disease, a viral disease, a fibrotic disease, a neurodegenerative disorder, pancreatitis or a renal disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a conjugate of the invention and optionally a second therapeutic agent.

[0338] In certain embodiments, the method inhibits abnormal cell growth or treats a proliferative disorder. In certain embodiments, the proliferative disorder is a cancer, such as a hematological cancer or a solid tumor. Exemplary hematological cancers include leukemia and lymphoma. Leukemia can be acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) such as acute B-lymphoblastic leukemia (B-ALL), chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL). Solid tumors can be melanoma, lung cancer (e.g., non-small cell lung cancer), ovarian cancer, endometrial cancer, peritoneal cancer, pancreatic cancer, breast cancer, prostate cancer or cervical cancer.

[0339] It should be understood that any embodiment described herein (including embodiments described only in one aspect of the invention and not in other aspects, and including embodiments appearing only in the examples) may be combined with any one or more other embodiments unless explicitly stated or inappropriate. BRIEF DESCRIPTION OF THE DRAWINGS

[0340] Figure 1A LC-MS of the deglycosylated conjugate huMOV19-C442-Mal-CX1-1-DM1 is shown, and the conjugate was found to have an average of 2 mol DM1 / mol antibody by UV-Vis; 99.3% monomer by SEC; and no detectable unbound DM1 by HPLC on a HISEP column.

[0341] Figure 1B LC-MS of the deglycosylated conjugate huMOV19-C442-Mal-SPDB-DM4 is shown, and the conjugate was found to have an average of 2 mol DM4 / mol antibody by UV-Vis; 99.5% monomer by SEC; and 0.8% unbound DM4 by HPLC on a HISEP column.

[0342] Figure 1CLC-MS of the deglycosylated conjugate huMOV19-C442-D5 is shown, and the conjugate was found to have an average of 2 mol D5 / mol antibody by UV / Vis; 94.6% monomer by SEC; and 0.8% unbound D5 by SEC / reverse phase HPLC.

[0343] Figure 1D LC-MS of the deglycosylated conjugate huMOV19-C442-D4 is shown, and the conjugate was found to have an average of 2 mol D4 / mol antibody by UV-Vis; and 93.6% monomer by SEC.

[0344] Figure 1E LC-MS of the deglycosylated conjugate huCD123-6Gv1.1S2-C442-D7 is shown, and the conjugate was found to have an average of 2 mol D7 / mol antibody by UV-Vis; 97.2% monomer by SEC; and 1.9% unbound D7 by SEC / reverse phase HPLC.

[0345] Figure 1F LC-MS of the deglycosylated conjugate huCD123-6Gv4.7-C442-D5 is shown, and the conjugate was found to have an average of 2 mol D5 / mol antibody by UV-Vis; and 94.8% monomer by SEC.

[0346] Figure 1G LC-MS of the deglycosylated conjugate huCD123-6Gv4.7-C442-D4 is shown, and the conjugate was found to have an average of 1.8 mol D4 / mol antibody by UV-Vis; and 97.4% monomer by SEC.

[0347] Figure 2 The binding substances that Cys is connected are shown to express the antigen (i.e., CD123) of the antibody recognition by the binding substances of the binding substances of the multiple target cell lines (e.g., AML cell line EOL-1, B-ALL cell line KOPN-8 and CML cell line MOLM-1) have at least the same activity as the binding substances that Lys is connected. The data curve connecting hollow squares and hollow circles represents the control with excessive unbound competitive antibodies (i.e., chCD123-6) for the curve connecting solid squares and solid circles respectively.

[0348] Figure 3A , 3BAnd 3C shows that the Cys-linked binder has at least the same activity as the Lys-linked binder on multiple target cell lines (e.g., KB cells, T47D cells, and KB cells, respectively) expressing the antigen (i.e., FRα) recognized by the antibody (i.e., M9346A or Mov19) of the binder. The data curve designated as "+B" is the corresponding control with excess unbound competing antibody (i.e., unbound M9346A antibody).

[0349] Figure 4A and 4B It was shown that the Cys-linked huMOV19-C442-D5 conjugate and the Lys-linked huMOV19-D2 conjugate had almost identical bystander killing potency in 300.19 cells.

[0350] Figure 5 The Cys-linked huMOV19-C442-D5 conjugate and the Lys-linked huMOV19-D2 conjugate were shown to have similar activity in the NCI-H2110 NSCLC xenograft model, regardless of the conjugate type (e.g., Lys-linked vs. Cys-linked). All mice that received a single intravenous injection of the indicated dose of the corresponding ADC after xenograft tumors reached approximately 100 mm 3 size.

[0351] Figure 6 Shown are the pharmacokinetics of huMOV19-C442-D5 ADC in CD1 mice over 28 days.

[0352] Fig. 7A Shown are individual percent body weight changes of female CD-1 mice treated with 200 μg / kg CysMab site-specific huMOV19-C442-D5. Figure 7B Shown are individual percent body weight changes of female CD-1 mice treated with 250 μg / kg CysMab site-specific huMOV19-C442-D5. Figure 7C Shown are individual percent body weight changes of female CD-1 mice treated with 100 μg / kg Lys-linked huMOV19-D2. Fig.7D Shown are individual percent body weight changes for female CD-1 mice treated with vehicle control or 175, 200, or 250 μg / kg of the site-specific huMOV19-C442-D5 conjugate.

[0353] Figure 8 It was shown that binding of the huCD123-6Gv4.7 antibody to the D4 and D5 compounds via a Cys-linkage only moderately affected the binding affinity of the conjugates. Detailed description

[0354] Reference will now be made in detail to certain embodiments of the present invention, examples of which are illustrated with the accompanying structures and structural formulas. Although the present invention will be described in conjunction with the enumerated embodiments, it will be appreciated that they are not intended to limit the present invention to the embodiments. On the contrary, the present invention is intended to encompass all alternatives, modifications, and equivalents that may be included within the scope of the invention as defined by the claims. Those skilled in the art will recognize that many methods and materials similar or comparable to those described herein may be used to practice the present invention.

[0355] It should be understood that any embodiment described herein, including those described under different aspects of the invention (e.g., compounds, compound-linker molecules, conjugates, compositions, methods of preparation and use) and different parts of this specification (including embodiments described only in the examples), can be combined with one or more other embodiments of the invention unless explicitly stated or inappropriate. Combinations of embodiments are not limited to those specific combinations claimed via multiple independent claims.

[0356] definition

[0357] As used herein, "alkyl" or "straight or branched alkyl" refers to a saturated straight or branched monovalent hydrocarbon radical having 1 to 20 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, -CH2CH(CH3)2), 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl), 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, 1-heptyl, 1-octyl, and the like. Preferably, the alkyl group has 1 to 10 carbon atoms. More preferably, the alkyl group has 1 to 4 carbon atoms.

[0358] "Alkenyl" or "straight or branched alkenyl" refers to a straight or branched monovalent hydrocarbon radical having 2 to 20 carbon atoms and at least one site of unsaturation (i.e., a carbon-carbon double bond), wherein alkenyl includes groups having "cis" and "trans" orientations or "E" and "Z" orientations. Examples include, but are not limited to, ethylenyl (vinyl) (-CH=CH2), allyl (-CH2CH=CH2), etc. Preferably, alkenyl has 2 to 10 carbon atoms. More preferably, alkyl has 2 to 4 carbon atoms.

[0359] "Alkynyl" or "straight or branched alkynyl" refers to a straight or branched monovalent hydrocarbon radical having 2 to 20 carbon atoms and at least one site of unsaturation (i.e., carbon-carbon triple bond). Examples include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, hexynyl, and the like. Preferably, the alkynyl has 2 to 10 carbon atoms. More preferably, the alkynyl has 2 to 4 carbon atoms.

[0360] The terms "cyclic alkyl" and "cycloalkyl" are used interchangeably. They refer to monovalent saturated carbocyclic groups. Preferably, the cyclic alkyl is a 3 to 7 membered monocyclic group. More preferably, the cyclic alkyl is a cyclohexyl group.

[0361] The term "cycloalkylalkyl" refers to an alkyl group as described above substituted with a cycloalkyl group.

[0362] The term "cycloalkenyl" refers to a carbocyclic group having at least one double bond in the ring structure.

[0363] The term "cyclic alkynyl" refers to a carbocyclic group having at least one triple bond in the ring structure.

[0364] "Aryl" means a monovalent aromatic hydrocarbon radical having 6 to 18 carbon atoms obtained by removing a hydrogen atom from a single carbon atom of a parent aromatic ring system. Some aryl groups are represented by "Ar" in the exemplary structures. Aryl groups include bicyclic groups comprising an aromatic ring fused to a saturated, partially unsaturated ring or an aromatic carbocyclic or heterocyclic ring. Typical aryl groups include, but are not limited to, groups derived from benzene (phenyl), substituted benzenes, naphthalene, anthracene, indenyl, indanyl, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthyl, and the like. Preferably, aryl is phenyl.

[0365] The terms "heterocycle", "heterocyclyl" and "heterocyclic ring" are used interchangeably herein and refer to a saturated or partially unsaturated (i.e., having one or more double and / or triple bonds within the ring) carbocyclic group having 3 to 18 ring atoms, wherein at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus and sulfur, and the remaining ring atoms are C, wherein one or more ring atoms are optionally substituted independently with one or more substituents described below. The heterocycle may be a monocyclic ring having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected from N, O, P and S) or a bicyclic ring having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P and S), for example: a bicyclic [4,5], [5,5], [5,6] or [6,6] system. Heterocycles are described in Paquette, Leo A.; "Principles of Modern Heterocyclic Chemistry" (WA Benjamin, New York, 1968), especially Chapters 1, 3, 4, 6, 7 and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950), especially Volumes 13, 14, 16, 19 and 28; and J. Am. Chem. Soc. (1960) 82: 5566. "Heterocyclic" also includes groups in which a heterocyclic group is fused to a saturated, partially unsaturated ring or an aromatic carbocyclic or heterocyclic ring. Examples of heterocycles include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepanyl, diazepinyl, thiazepanyl, Heptyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolane, pyrazolyl, dithiolanyl, dithiolanyl, dihydropyranyl, dihydrothiophenyl, dihydrofuranyl, pyrazolidinyl imidazolinyl, imidazolidinyl, 3-azabicyclo [3.1.0] hexyl, 3-azabicyclo [4.1.0] heptyl and azabicyclo [2.2.2] hexyl. Spirocyclic moieties are also included within the scope of this definition. Examples of heterocyclic groups where ring atoms are partially substituted with oxo (=O) are pyrimidone and 1,1-dioxo-thiomorpholinyl.

[0366] As used herein, "5- or 6-membered nitrogen-containing heterocycle" refers to a heterocycle having 5 or 6 ring atoms and at least one nitrogen ring atom. It may optionally further contain 1 to 3 heteroatoms selected from O, N and S.

[0367] The term "heteroaryl" refers to a monovalent aromatic group having 5 or 6 ring members and includes fused ring systems (at least one of which is aromatic) having 5 to 18 atoms and containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur. Examples of heteroaryl groups are pyridyl (including, for example, 2-hydroxypyridyl), imidazolyl, imidazopyridyl, pyrimidinyl (including, for example, 4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furanyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothienyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl.

[0368] Where possible, the heterocycle or heteroaryl may be carbon (carbon-linked) or nitrogen (nitrogen-linked). For example and without limitation, a carbon-bonded heterocycle or heteroaryl is bonded at the 2, 3, 4, 5, or 6 position of pyridine; the 3, 4, 5, or 6 position of pyridazine; the 2, 4, 5, or 6 position of pyrimidine; the 2, 3, 5, or 6 position of pyrazine; the 2, 3, 4, or 5 position of furan, tetrahydrofuran, thiofuran, thiophene, pyrrole, or tetrahydropyrrole; the 2, 4, or 5 position of oxazole, imidazole, or thiazole; the 3, 4, or 5 position of isoxazole, pyrazole, or isothiazole; the 2 or 3 position of aziridine; the 2, 3, or 4 position of azetidine; the 2, 3, 4, 5, 6, 7, or 8 position of quinoline; or the 1, 3, 4, 5, 6, 7, or 8 position of isoquinoline.

[0369] For example, and without limitation, the nitrogen-bonded heterocycle or heteroaryl is bonded at the 1 position of aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazoline, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole; the 2 position of isoindole or isoindoline; the 4 position of morpholine; and the 9 position of carbazole or or O-carboline.

[0370] The heteroatoms present in the heteroaryl or heterocyclyl groups include oxidized forms such as NO, SO and SO2.

[0371] The term "halo" or "halogen" refers to F, Cl, Br or I.

[0372] As used herein, the term "haloalkyl" refers to an alkyl group as defined herein substituted with one or more halogen groups as defined herein. The haloalkyl group may be a monohaloalkyl group, a dihaloalkyl group, or a polyhaloalkyl group. The monohaloalkyl group may have a fluoro, chloro, bromo, or iodo substituent. The dihaloalkyl group or the polyhaloalkyl group may be substituted with a combination of two or more identical halogen atoms or different halogen groups. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, and dichloropropyl.

[0373] As used herein, "alkoxy" refers to alkyl-O-, wherein alkyl is defined herein above. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, and the like.

[0374] The above alkyl, haloalkyl, alkoxy, alkenyl, alkynyl, cyclic alkyl, cyclic alkenyl, cyclic alkynyl, carbocyclic, aryl, heterocyclic and heteroaryl groups may be optionally substituted with one or more (e.g., 2, 3, 4, 5, 6 or more) substituents.

[0375] If a substituent is described as "substituted," then a non-hydrogen substituent is in the place of a hydrogen substituent on a carbon, oxygen, sulfur, or nitrogen of the substituent. Thus, for example, a substituted alkyl substituent is an alkyl substituent in which at least one non-hydrogen substituent replaces a hydrogen substituent on the alkyl substituent. For ease of illustration, a monofluoroalkyl is an alkyl substituted with a fluorine substituent, and a difluoroalkyl is an alkyl substituted with two fluorine substituents. It should be recognized that if more than one substitution is present on a substituent, each non-hydrogen substituent may be the same or different (unless otherwise specified).

[0376] If a substituent is described as "optionally substituted," the substituent may be (1) unsubstituted or (2) substituted. If a carbon of a substituent is described as substituted with one or more of the optional substituents listed, then one or more hydrogens on the carbon (if any) may be replaced, individually and / or together, with independently selected optional substituents. If a nitrogen of a substituent is described as substituted with one or more of the optional substituents listed, then one or more hydrogens on the nitrogen (if any) may each be replaced with independently selected optional substituents. An exemplary substituent may be described as -NR'R", wherein R' and R" together with the nitrogen atom to which they are attached may form a heterocyclic ring. The heterocyclic ring formed by R' and R" together with the nitrogen atom to which they are attached may be partially or fully saturated. In one embodiment, the heterocyclic ring consists of 3 to 7 atoms. In another embodiment, the heterocyclic ring is selected from the group consisting of pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, pyridinyl, and thiazolyl.

[0377] As used herein, the terms "substituent" and "radical" or "group" are interchangeable.

[0378] If a group of substituents is collectively described as being substituted with one or more of a list of optional substituents, the group may include: (1) non-substituents, (2) substitutable substituents that are not substituted with the optional substituents, and / or (3) substitutable substituents that are substituted with one or more optional substituents.

[0379] If a substituent is described as optionally substituted with up to a specified number of non-hydrogen substituents, then the substituent may be (1) unsubstituted; or (2) substituted with up to the specified number of non-hydrogen substituents or up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen substituents, then any heteroaryl having less than 3 substitutable positions will be optionally substituted with up to the number of non-hydrogen substituents that the heteroaryl has substitutable positions. In non-limiting examples, the substituent may be selected from a straight chain, branched chain, or cyclic alkyl, alkenyl, or alkynyl group having from 1 to 10 carbon atoms; an aryl, heteroaryl, heterocyclyl, halogen, guanidine [-NH(C=NH)NH2], -OR 100 NR 101 R 102 、-NO2、-NR 101 COR 102 、-SR 100 , with -SOR 101 Sulfoxide represented by -SO2R 101 Sulfone, sulfonate -SO3M, sulfate -OSO3M, -SO2NR 101 R 102 Sulfonamide, cyano, azido, -COR 101 、-OCOR 101 、-OCONR 101 R 102 And polyethylene glycol units (-OCH2CH2) n R 101 , where M is H or a cation (such as Na + or K + );R 101 , R 102 and R 103 Each independently selected from H, a linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit (-OCH2CH2) n -R 104(wherein n is an integer from 1 to 24), an aryl group having 6 to 10 carbon atoms, a heterocyclic ring having 3 to 10 carbon atoms, and a heteroaryl group having 5 to 10 carbon atoms; and R 104 is H or a straight or branched chain alkyl group having 1 to 4 carbon atoms, wherein R 100 , R 101 , R 102 , R 103 and R 104 The alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclic groups in the groups represented by are optionally substituted with one or more (e.g., 2, 3, 4, 5, 6 or more) substituents independently selected from the following groups: halogen, -OH, -CN, -NO2 and unsubstituted straight or branched chain alkyl groups having 1 to 4 carbon atoms. Preferably, the substituents of the above-mentioned alkyl, alkenyl, alkynyl, cyclic alkyl, cyclic alkenyl, cyclic alkynyl, carbocyclic group, aryl, heterocyclic group and heteroaryl groups optionally substituted include halogen, -CN, -NR 102 R 103、 -CF3, -OR 101 , aryl, heteroaryl, heterocyclic, -SR 101 、-SOR 101 、-SO2R 101 and -SO3M.

[0380] The number of carbon atoms in a group can be determined herein by the prefix "C x-xx ” or “C x -C xx ", where x and xx are integers. For example, "C 1-4 "Alkyl" or "C1-C4 alkyl" is an alkyl group having 1 to 4 carbon atoms.

[0381] The terms "compound" or "cytotoxic compound", "cytotoxic dimer" and "cytotoxic dimer compound" are used interchangeably. They are intended to include compounds whose structure or formula or any derivatives have been disclosed in the present invention or whose structure or formula or any derivatives are incorporated by reference. The term also includes stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts (e.g., pharmaceutically acceptable salts) and prodrugs and salts of prodrugs of all formulas disclosed in the present invention. The term also includes any solvates, hydrates and polymorphs of any of the foregoing. The specific statements about "stereoisomers", "geometric isomers", "tautomers", "solvates", "metabolites", "salts", "prodrugs", "prodrug salts", "conjugates", "conjugate salts", "solvates", "hydrates" or "polymorphs" in certain aspects of the present invention described in this application should not be interpreted as intending that the use of the term "compound" omit these forms in other aspects of the present invention that are not stated in these other forms.

[0382] As used herein, the term "conjugate" refers to a compound described herein or a derivative thereof linked to a cell binding agent.

[0383] As used herein, the term "linkable to a cell binding agent" means that the compounds or derivatives thereof described herein contain at least one linking group or a precursor thereof suitable for bonding these compounds or derivatives thereof to a cell binding agent.

[0384] The term "precursor" of a given group refers to any group that can generate said group by any deprotection, chemical modification or coupling reaction.

[0385] The term "chiral" refers to the property of a molecule that it is non-superimposable on its mirror image partner, while the term "achiral" refers to the property of a molecule that it is superimposable on its mirror image partner.

[0386] The term "stereoisomers" refers to compounds that have identical chemical constitution and connectivity but differ in the orientation of the atoms in space and are not interconvertible by rotation about single bonds.

[0387] "Diastereoisomers" refer to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Diastereomeric mixtures can be separated by high-resolution analytical procedures such as crystallization, electrophoresis, and chromatography.

[0388] "Enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of one another.

[0389] The stereochemical definitions and conventions used herein generally follow SP Parker, ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds," John Wiley & Sons, Inc., New York, 1994. The compounds of the present invention may contain asymmetric or chiral centers and therefore exist in different stereoisomeric forms. It is contemplated that all stereoisomeric forms of the compounds of the present invention, including but not limited to non-mirror isomers, mirror isomers, and atropisomers, as well as mixtures thereof (such as racemic mixtures), form part of the present invention. Many organic compounds exist in optically active forms, i.e., they are able to rotate the plane of plane polarized light. When describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule around its chiral center. The prefixes d and I or (+) and (-) are used to indicate the sign of the rotation of plane polarized light by the compound, where (-) or 1 means that the compound is levorotatory. Compounds prefixed with (+) or d are dextrorotatory compounds. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers may also be referred to as mirror image isomers, and mixtures of these isomers are often referred to as mirror image isomeric mixtures. A 50:50 mixture of mirror image isomers is called a racemic mixture or racemate, which may occur when stereoselectivity or stereospecificity is not present in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two mirror image isomeric substances that lack optical activity.

[0390] The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions that occur via proton migration, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions that occur by rearrangement of some of the bonded electrons.

[0391] A preferred form of the prodrugs of the present invention includes compounds of the present invention (with or without any linker groups) and conjugates comprising an adduct formed between the imine bond of the compound / conjugate and an imine-reactive reagent. Another preferred form of the prodrugs of the present invention includes compounds such as formula (I)-(IV), wherein when the double linear bond between N and C When X represents a single bond, X is H or an amine protecting group, and the compound becomes a prodrug. The prodrug of the present invention may contain one or two of the prodrug forms described herein (e.g., containing an adduct formed between the imine bond of the compound / conjugate and the imine-reactive reagent, and / or containing a Y leaving group when X is -H).

[0392] The term "imine-reactive reagent" refers to a reagent that is capable of reacting with an imine group. Examples of imine-reactive reagents include, but are not limited to, sulfites (H2SO3, H2SO2, or HSO3 - 、SO3 2- or HSO2 - salts with cations), metabisulfite (H2S2O5 or S2O5 2- salts with cations), mono-, di-, tri-, and tetra-thiophosphates (PO3SH3, PO2S2H3, POS3H3, PS4H3, or PO3S 3- PO2S2 3- POS3 3- or PS4 3- salts with cations), phosphorothioates ((R i O)2PS(OR i ), R i SH, R i SOH, R i SO2H、R i SO3H), various amines (hydroxylamine (such as NH2OH), hydrazine (such as NH2NH2), NH2O-R i , R i 'NH-R i NH2-R i ), NH2-CO-NH2, NH2-C(=S)-NH2, thiosulfate (H2S2O3 or S2O3 2- salts with cations), dithionites (H2S2O4 or S2O4 2- with cations), dithiophosphates (P(=S)(OR k )(SH)(OH) or its salt with cations), hydroxamic acid (R k C(=O)NHOH or salts formed with cations), hydrazide (R k CONHNH2), formaldehyde sulfoxylate (HOCH2SO2H or HOCH2SO2 - Salts with cations, such as HOCH2SO2 - Na + ), glycosylated nucleotides (such as GDP-mannose), fludarabine or a mixture thereof, wherein R iand R i’ Each independently is a straight chain or branched chain alkyl group having 1 to 10 carbon atoms and is substituted with at least one selected from -N(R j )2, -CO2H, -SO3H and -PO3H; R i and R i’ may be further optionally substituted with alkyl substituents as described herein; R j is a straight or branched chain alkyl group having 1 to 6 carbon atoms; and R k is a linear, branched or cyclic alkyl, alkenyl or alkynyl group, aryl, heterocyclic group or heteroaryl group having 1 to 10 carbon atoms (preferably, R k is a straight or branched chain alkyl group having 1 to 4 carbon atoms; more preferably, R k Preferably, the cation is a monovalent cation, such as Na + or K + Preferably, the imine-reactive reagent is selected from sulfite, hydroxylamine, urea and hydrazine. More preferably, the imine-reactive reagent is NaHSO3 or KHSO3.

[0393] As used herein, a "benzodiazepine" compound is a compound having a benzodiazepine core structure. The benzodiazepine core may be substituted with and / or fused to one or more ring structures. It also includes compounds having two benzodiazepine cores connected by a linker. The imine functional group (-C=N-) that is part of the benzodiazepine core may be reduced.

[0394] As used herein, an "indolinobenzodiazepine" (IBD) compound is a compound having an indolinobenzodiazepine core structure. The indolinobenzodiazepine may be substituted. It also includes compounds having two indolinobenzodiazepine cores connected by a linker. The imine functional group (-C=N-) that is part of the indolinobenzodiazepine core may be reduced.

[0395] As used herein, the phrase "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the invention. Exemplary salts include, but are not limited to, sulfates, citrates, acetates, oxalates, chlorides, bromides, iodides, nitrates, bisulfates, phosphates, acid phosphates, isonicotinates, lactates, salicylates, acid citrates, tartrates, oleates, tannates, pantothenates, bitartrates, ascorbates, succinates, maleates, gentisinates, fumarates, gluconates, glucuronates, saccharates, formates, benzoates, glutamates, methanesulfonates "mesylate", ethanesulfonates, benzenesulfonates, p-toluenesulfonates, pamoates (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)), alkali metal (e.g., sodium and potassium) salts, alkaline earth metal (e.g., magnesium) salts, and ammonium salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule, such as an acetate ion, a succinate ion, or other counter ion. The counter ion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. In addition, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Cases where multiple charged atoms are part of a pharmaceutically acceptable salt may have multiple counter ions. Thus, a pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counter ions.

[0396] If the compound of the invention is a base, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, by treating the free base with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid, or with an organic acid such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acid (such as glucuronic acid or galacturonic acid), alpha hydroxy acid (such as citric acid or tartaric acid), amino acid (such as aspartic acid or glutamic acid), aromatic acid (such as benzoic acid or cinnamic acid), sulfonic acid (such as p-toluenesulfonic acid or ethanesulfonic acid).

[0397] If the compound of the invention is an acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, by treating the free acid with an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or an alkaline earth metal hydroxide. Illustrative examples of suitable salts include, but are not limited to, organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary and tertiary amines and cyclic amines such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.

[0398] As used herein, the term "solvate" means a compound that further includes a stoichiometric or non-stoichiometric amount of a solvent (such as water, isopropanol, acetone, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine dichloromethane, 2-propanol, etc.) bound by non-covalent intermolecular forces. Solvates or hydrates of the compounds are readily prepared by adding at least 1 molar equivalent of a hydroxyl solvent (such as methanol, ethanol, 1-propanol, 2-propanol, or water) to the compound to cause solvation or hydration of the imine moiety.

[0399] The terms "abnormal cell growth" and "proliferative disorder" are used interchangeably in this application. Unless otherwise indicated, as used herein, "abnormal cell growth" refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes, for example, abnormal growth of the following: (1) tumor cells (tumors) that proliferate by expressing mutant tyrosine kinases or overexpressing receptor tyrosine kinases; (2) benign and malignant cells of other proliferative diseases with abnormal tyrosine kinase activation; (3) any tumor that proliferates due to receptor tyrosine kinases; (4) any tumor that proliferates due to abnormal serine / threonine kinase activation; and (5) benign and malignant cells of other proliferative diseases with abnormal serine / threonine kinase activation.

[0400] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. A "tumor" comprises one or more cancerous and / or benign or precancerous cells.

[0401] "Therapeutic agent" encompasses biological agents or chemotherapeutic agents such as antibodies, peptides, proteins, enzymes, etc. Therapeutic agents also encompass immunoconjugates of cell binding agents (CBA) and chemical compounds, such as antibody-drug conjugates (ADCs). The drug in the conjugate may be a cytotoxic agent, such as the cytotoxic agents described herein.

[0402] A "chemotherapeutic agent" is a chemical compound useful in treating cancer.

[0403] "Metabolites" or "catabolites" are products produced by the metabolism or catabolism of a particular compound, its derivatives or conjugates, or its salts in vivo. Metabolites of compounds, their derivatives or conjugates can be identified using conventional techniques known in the art, and their activity can be determined using tests such as those described herein. These products can be produced, for example, by oxidation, hydroxylation, reduction, hydrolysis, amination, deamination, esterification, deesterification, enzymatic cleavage, etc. of the administered compound. Therefore, the present invention includes metabolites of compounds of the present invention, their derivatives or conjugates (including compounds, their derivatives or conjugates) prepared by a method comprising contacting a compound of the present invention, its derivatives or conjugates with a mammal for a period of time sufficient to produce a metabolic product thereof.

[0404] The phrase "pharmaceutically acceptable" means that the substance or composition must be compatible chemically and / or toxicologically with the other ingredients making up the formulation and / or the mammal to be treated therewith.

[0405] The term "protecting group" or "protecting moiety" refers to a substituent commonly used to block or protect a specific functional group when other functional groups on a compound, its derivative, or its conjugate react. For example, an "amine protecting group" or "amino protecting moiety" is a substituent attached to an amino group to block or protect the amino functional group in the compound. These groups are well known in the art (see, for example, P. Wuts and T. Greene, 2007, Protective Groups in Organic Synthesis, Chapter 7, J. Wiley & Sons, NJ) and are exemplified by carbamates such as methyl carbamate and ethyl carbamate, FMOC, substituted ethyl carbamates, carbamates that are cleaved by 1,6-β-elimination reactions (also referred to as "self-consumption (self immolative)"); urea; amide; peptide; alkyl and aryl derivatives. Suitable amino protecting groups include acetyl, trifluoroacetyl, tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethyleneoxycarbonyl (Fmoc). For a general description of protecting groups and their uses, see PGM Wuts & T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 2007.

[0406] The term "leaving group" refers to a group having a charged or uncharged moiety that leaves during substitution or displacement. Such leaving groups are well known in the art and include, but are not limited to, halogens, esters, alkoxy groups, hydroxyls, tosylates, triflates, mesylates, nitrites, azidos, carbamates, disulfides, thioesters, thioethers, and diazo compounds.

[0407] The term "bifunctional cross-linker", "bifunctional linker" or "cross-linker" refers to a modifier having two reactive groups, one of which is capable of reacting with a cell-binding agent and the other of which is capable of reacting with a cytotoxic compound to link the two moieties together. These bifunctional cross-linkers are well known in the art (see, e.g., Isalm and Dentin Bioconjugation, Chapter 5, pp. 218-363, Groves Dictionaries Inc. New York, 1999). For example, bifunctional cross-linkers capable of linking via thioether bonds include N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC) for the introduction of maleimido groups or N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB) for the introduction of iodoacetyl groups.Other bifunctional cross-linking agents that introduce maleimido or haloacetyl groups onto cell binding agents are well known in the art (see U.S. Patent Applications 2008 / 0050310, 20050169933, available from Pierce Biotechnology Inc. PO Box 117, Rockland, IL 61105, USA) and include (but are not limited to) bis-maleimido polyethylene glycol (BMPEO), BM(PEO)2, BM(PEO)3, N-(β-maleimidopropoxy) succinimide ester (BMPS), γ-maleimidobutyric acid N-succinimide ester (GMBS), ε-maleimidocaproic acid N-hydroxysuccinimide ester (EMCS), 5-maleimidopentanoic acid NHS, HBVS, N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxy-(6-amido)- esters), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-maleimidophenyl)-butyric acid hydrazide or hydrochloride (MPBH), 3-(bromoacetamido)propionic acid N-succinimidyl ester (SBAP), iodoacetic acid N-succinimidyl ester (SIA), kappa-maleimidoundecanoic acid N-succinimidyl ester (KMUA), 4-(4-maleimidophenyl)-butyric acid N-succinimidyl ester (SMPB), succinimidyl- ... 6-(β-maleimidopropionamide) hexanoate (SMPH), succinimidyl-(4-vinylsulfonyl) benzoate (SVSB), disulfide bis-maleimidoethane (DTME), 1,4-bis-maleimidobutane (BMB), 1,4-bismaleimido-2,3-dihydroxybutane (BMDB), bis-maleimidohexane (BMH), bis-maleimidoethane (BMOE), 4-(N-maleimido-methyl)cyclohexane-1-carboxylic acid sulfosuccinimidyl ester (sulfo-SMCC), sulfosuccinimidyl Imido (4-iodo-acetyl) aminobenzoate (sulfo-SIAB), m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (sulfo-MBS), N-(γ-maleimidobutyryloxy)sulfosuccinimide ester (sulfo-GMBS), N-(ε-maleimidocaproyloxy)sulfosuccinimide ester (sulfo-EMCS), N-(K-maleimidocaproyloxy)sulfosuccinimide ester (sulfo-KMUS) and 4-(p-maleimidophenyl)butyric acid sulfosuccinimide ester (sulfo-SMPB).

[0408] Heterobifunctional crosslinkers are bifunctional crosslinkers with two different reactive groups. Heterobifunctional crosslinkers containing an amine-reactive N-hydroxysuccinimide group (NHS group) and a carbonyl-reactive hydrazine group can also be used to connect the cytotoxic compounds described herein to cell binding agents (e.g., antibodies). Examples of commercially available heterobifunctional crosslinkers include succinimidyl 6-hydrazino nicotinamide acetone hydrazone (SANH), 4-hydrazino terephthalic acid succinimidyl ester hydrochloride (SHTH), and succinimidyl nicotinic acid hydrazine hydrochloride (SHNH). Benzodiazepine derivatives of the present invention with hydrazine can also be used to prepare conjugates with acid-labile linkages. Examples of available bifunctional crosslinkers include succinimidyl-p-formyl benzoate (SFB) and succinimidyl-p-formyl phenoxyacetate (SFPA).

[0409] Bifunctional cross-linking agents capable of linking a cell-binding agent to a cytotoxic compound via a disulfide bond are known in the art and include N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), N-succinimidyl-4-(2-pyridyldithio) pentanoate (SPP), N-succinimidyl-4-(2-pyridyldithio) butyrate (SPDB), N-succinimidyl-4-(2-pyridyldithio) 2-sulfobutyrate (sulfo-SPDB) for introducing disulfide pyridyl groups. Other bifunctional cross-linking agents that can be used to introduce disulfide groups are known in the art and are disclosed in: U.S. Pat. Nos. 6,913,748, 6,716,821, and U.S. Patent Publications 20090274713 and 20100129314, all of which are incorporated herein by reference. Alternatively, a cross-linking agent that introduces a thiol group, such as 2-iminothiolane, homocysteine ​​thiolactone, or S-acetylsuccinic anhydride, may also be used.

[0410] As defined herein, a "linker," "linker moiety," or "linking group" refers to a moiety that connects two groups, such as a cell-binding agent and a cytotoxic compound. Typically, a linker is substantially inert under the conditions under which the two groups to which it is connected are connected. A bifunctional cross-linking agent may comprise two reactive groups, one at each end of the linker moiety, such that one reactive group may first react with the cytotoxic compound to provide a compound with a linker moiety and a second reactive group, which may then react with the cell-binding agent. Alternatively, one end of the bifunctional cross-linking agent may first react with the cell-binding agent to provide a cell-binding agent with a linker moiety and a second reactive group, which may then react with the cytotoxic compound. The linking moiety may contain a chemical bond that allows the cytotoxic moiety to be released at a specific site. Suitable chemical bonds are well known in the art and include disulfide bonds, thioether bonds, acid-labile bonds, photolabile bonds, peptidase-labile bonds, and esterase-labile bonds (see, e.g., U.S. Pat. Nos. 5,208,020; 5,475,092; 6,441,163; 6,716,821; 6,913,748; 7,276,497; 7,276,499; 7,368,565; 7,388,026 and 7,414,073). Disulfide bonds, thioether bonds, and peptidase-labile bonds are preferred. Other linkers that can be used in the present invention include non-cleavable linkers, such as those described in detail in U.S. Publication No. 20050169933; or charged linkers or hydrophilic linkers, which are described in US 2009 / 0274713, US 2010 / 01293140, and WO 2009 / 134976, each of which is expressly incorporated herein by reference.

[0411] In one embodiment, the linking group having a reactive group (such as a reactive ester) attached to one end is selected from the following groups: -O(CR 20 R 21 ) m (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-O(CR 20 R 21 ) m (CR 26 =CR 27 ) m’ (CR 22 R23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”, -O(CR 20 R 21 ) m (alkynyl) n’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”, -O(CR 20 R 21 ) m (piperazinyl) t’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”, -O(CR 20 R 21 ) m (pyrrolyl) t’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”, -O(CR 20 R 21 ) m A” n” (CR 22 R 23 ) n (OCH2CH2) p(CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-S(CR 20 R 21 ) m (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-S(CR 20 R 21 ) m (CR 26 =CR 27 ) m’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-S(CR 20 R 21 ) m (alkynyl group) n’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-S(CR 20 R 21 ) m (piperazinyl group) t’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 )p” Y”(CR 24 R 25 ) q (CO) t X”、-S(CR 20 R 21 ) m (pyrrolyl) t’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-S(CR 20 R 21 ) m A” m” (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-NR 33 (C=O) p” (CR 20 R 21 ) m (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-NR 33 (C=O) p” (CR 20 R 21 ) m (CR 26 =CR 27 ) m’ (CR 22 R 23 ) n (OCH2CH2) p (CR40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-NR 33 (C=O) p” (CR 20 R 21 ) m (alkynyl 1) n’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q -(CO) t X”、-NR 33 (C=O) p” (CR 20 R 21 ) m (piperazinyl) t’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-NR 33 (C=O) p” (CR 20 R 21 ) m (pyrrolyl) t’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q - (CO) t X”、-NR 33 (C=O) p” (CR 20 R 21 )m A” m” (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-(CR 20 R 21 ) m (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-(CR 20 R 21 ) m (CR 26 =CR 27 ) m’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-(CR 20 R 21 ) m (alkynyl) n’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-(CR 20 R 21 ) m (piperazinyl) t’ (CR22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-(CR 20 R 21 ) m A” m” (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-(CR 20 R 21 ) m (CR 29 =N-NR 30 ) n” (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-(CR 20 R 21 ) m (CR 29 =N-NR 30 ) n” (CR 26 =CR 27 ) m’ (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X”、-(CR20 R 21 ) m (CR 29 =N-NR 30 ) n” (Alkynyl) n, (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q - (CO) t X”,-(CR 20 R 21 ) m (CR 29 =N-NR 30 ) n” A” m” (CR 22 R 23 ) n (OCH2CH2) p (CR 40 R 41 ) p” Y”(CR 24 R 25 ) q (CO) t X",

[0412] in:

[0413] m, n, p, q, m', n', t' are integers from 1 to 10, or are optionally 0;

[0414] t, m'', n'' and p'' are 0 or 1;

[0415] X" is selected from OR 36 , SR 37 NR 38 R 39 , where R 36 , R 37 , R 38 , R 39 is H, or a linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 20 carbon atoms and or a polyethylene glycol unit -(OCH2CH2) n ; R 37Optionally, a thiol protecting group, when t=1, COX" forms a reactive ester selected from the group consisting of N-hydroxysuccinimide esters, N-hydroxyphthalimide esters, N-hydroxysulfo-succinimide esters, p-nitrophenyl esters, dinitrophenyl esters, pentafluorophenyl esters, and derivatives thereof, wherein the derivatives facilitate amide bond formation;

[0416] Y" is absent or selected from O, S, SS or NR 32 , where R 32 has the same definition as given above for R; or

[0417] When Y" is not SS and t=0, X" is selected from maleimide, haloacetyl or SR 37 , where R 37 has the same definition as above;

[0418] A" is an amino acid residue or a polypeptide containing 2 to 20 amino acid units;

[0419] R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 and R 27 are the same or different and are -H or a straight or branched chain alkyl group having 1 to 5 carbon atoms;

[0420] R 29 With R 30 are the same or different and are -H or an alkyl group having 1 to 5 carbon atoms;

[0421] R 33 is -H or a linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 12 carbon atoms, a polyethylene glycol unit R-(OCH2CH2) n -, or R 33 For-COR 34 、-CSR 34 、-SOR 34 or-SO2R 34 , where R 34 is H or a linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 20 carbon atoms, or a polyethylene glycol unit -(OCH2CH2) n ;and

[0422] R 40 and R 41 One of them is optionally a negatively or positively charged functional group, and the other is H or an alkyl, alkenyl, or alkynyl group having 1 to 4 carbon atoms.

[0423] Any of the above-described linking groups may be present in any Compound, Drug-Linker Compound, or Conjugate of the invention, including a linking group substituted for any of the formulae described herein.

[0424] The term "amino acid" refers to a naturally occurring amino acid or a non-naturally occurring amino acid. In one embodiment, the amino acid is NH2-C(R aa’ R aa )-C(=O)OH, wherein R aa and R aa’ are each independently H; an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms; an aryl group; a heteroaryl group; or a heterocyclyl group; or R aa The term "amino acid residue" refers to the corresponding residue obtained when one hydrogen atom is removed from the amine and / or carboxyl terminus of an amino acid, such as -NH-C(R aa’ R aa )-C(=O)O-.

[0425] The term "cation" refers to an ion with a positive charge. A cation can be monovalent (e.g., Na + , K + etc.), divalent (e.g. Ca 2 + Mg 2+ etc.) or polyvalent (e.g. Al 3+ Preferably, the cation is monovalent.

[0426] The term "therapeutically effective amount" means the amount of active compound or conjugate that causes the desired biological response in the subject. The response includes alleviating the symptoms of the disease or condition being treated; preventing, inhibiting or delaying the recurrence of disease symptoms or the disease itself; increasing the life span of the subject compared to the absence of the treatment; or preventing, inhibiting or delaying the development of disease symptoms or the disease itself. The determination of the effective amount is within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein. The toxicity and therapeutic efficacy of the compound or conjugate can be determined by standard pharmaceutical procedures in cell culture and experimental animals. The effective amount of the compound or conjugate of the present invention or other therapeutic agent to be administered to the subject will depend on the stage, type and state of the multiple myeloma, as well as the characteristics of the subject, such as general health, age, sex, weight and drug resistance. The effective amount of the compound or conjugate of the present invention or other therapeutic agent to be administered also depends on the route of administration and dosage form. The dose and interval can be adjusted individually to provide a plasma level of the active compound sufficient to maintain the desired therapeutic effect.

[0427] The term "cysteine ​​engineered antibody" includes antibodies with at least one Cys that is not normally present at a given residue of an antibody light chain or heavy chain. The Cys (also referred to as "engineered Cys") may be introduced, for example, by standard recombinant techniques (e.g., by replacing the coding sequence of a non-Cys residue at a target residue with a coding sequence of a Cys). In certain embodiments, the Cys engineered antibodies of the present invention have an engineered Cys in the heavy chain. In certain embodiments, the engineered Cys is located at or near the CH3 domain of the heavy chain. In certain embodiments, the engineered Cys is at residue 442 of the heavy chain (EU / OU numbering).

[0428] As used herein, all antibody amino acid residues described herein are numbered according to the EU index, Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, NIH Publication No. 91-3242, 1991 (EU / OU numbering, the entire contents of which are incorporated herein by reference). Common isotypes are referred to as G1, G2, G4, etc.

[0429] Some examples below refer to various humanized anti-CD123 antibodies, and the nomenclature of these antibodies is briefly described herein. A class of huCD123-6 antibodies is humanized by transplanting 6 CDRs from the heavy chain and light chain of murine anti-CD123 antibody muCD123-6. In those antibodies, the letter "G" is followed by the clone name (i.e., huCD123-6), and the clone name is followed by the version number of the source of the specified human light chain and heavy chain variable region sequence. Therefore, huCD123-6Gv4.6 refers to the humanized CD123 antibodies based on transplanting ("G") 6 CDR regions from corresponding muCDR123-6 antibodies to human light chain variable region Gv4 and heavy chain variable region Gv6. Similarly, -Gv4.7 includes human light chain variable region Gv4 and heavy chain variable region Gv7.

[0430] Another type of huCD123-6 antibody is humanized by resurfacing. The resurfaced antibody having the resurfaced heavy chain sequence huCD123-6rhv1.1 and the resurfaced light chain sequence huCD123-6rlv1.0 is huCD123-6Rv1.1.

[0431] When any anti-CD123 antibody includes engineered Cys residues as described above, the antibody may include name CysMab or C442, such as huCD123-6Gv4.7-C442. C442 residues can be combined with cytotoxic drugs / cytotoxic agents via the free thiol groups of C442 residues, such as by reacting with the thiol reactive agent (e.g., maleimido) of cytotoxic drugs. These cytotoxic drugs with thiol reactive groups-D4-D7- and their synthesized representative lists are described in Example 1 and are listed in the following table. Additional related compounds D1, D2, DGN462 and D3 (which have the same core structure with D4, D5, D6 and D7, respectively, but do not have thiol reactive groups) are also listed below. D1-D3 and DGN462 can not be connected to C442 due to lack of maleimido thiol reactive groups.

[0432]

[0433]

[0434] The antibody of the present invention and D4-D7 via the conjugate of free thiol group simply lists the name of antibody and connected cytotoxic drug. For example, huCD123-6Gv4.7-C442-D5 is the conjugate of compound D5 and huCD123-6Gv4.7 via C442 thiol group, and huMov19-C442-D5 is the conjugate of compound D5 and huMov19 antibody via C442 thiol group. In certain embodiments, compounds such as D1 require additional linkers (e.g., sulfo-SPDB linkers or sSPDB) to be bound to the antibody, such as being bound to the Lys side chain amino group. The structure of the conjugate huCD123-6Gv4.7-sulfo-SPDB-D1 (or huCD123-6Gv4.7-sulfo-SPDB-D1) connected by Lys is shown below.

[0435]

[0436] It should be noted that some CD123 antibodies have "S2" and / or "S3" in the names of such antibodies or their immunoconjugates, which should not be confused with the "s2" or "s3" designations in chemical formulas indicating the site of attachment or covalent bond formation.

[0437] Conjugates and compounds of the invention

[0438] In a first aspect, the invention provides a cell-binding agent-cytotoxic agent conjugate, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent via a thiol (-SH) group located on the CBA. In certain embodiments, the free thiol group is on an engineered Cys residue in the heavy chain CH3 region of an antibody, at EU / OU numbering position 442 (or C442 for short) of the heavy chain.

[0439] Thus, in one embodiment, the antibody-cytotoxic agent conjugate of the invention comprises an antibody having a cysteine ​​residue (e.g., at EU / OU numbering position 442 of the heavy chain) and a cytotoxic agent, wherein the antibody is covalently linked to the cytotoxic agent via the cysteine ​​residue (e.g., C442). The conjugate is represented by the following formula:

[0440]

[0441] in:

[0442] Ab is an antibody having a cysteine ​​residue at position 442 (EU / OU numbering) of the heavy chain;

[0443] S 442 Denotes the covalent attachment to J CB 'a thiol group of the cysteine ​​residue at position 442 of the heavy chain of the antibody of the group;

[0444] J CB ' is a connecting part connecting the cysteine ​​residue and the group L;

[0445] L is the linker between the cytotoxic agent and J CB 'Partial joint;

[0446] D is a cytotoxic agent covalently linked to group L; and

[0447] w is 1 or 2.

[0448] In one embodiment, the cysteine ​​residue at position 442 is recombinantly introduced into said Ab.

[0449] In a second aspect, the present invention provides a cytotoxic agent-linker compound capable of reacting with an antibody of the present invention having a free cysteine ​​residue to form a conjugate of the present invention.

[0450] In one embodiment, the cytotoxic agent-linker compound of the invention is represented by the following structural formula:

[0451] DLJ CB (II)

[0452] in:

[0453] JCB is a linking group capable of forming a covalent bond with the antibodies described herein;

[0454] L is a linker between the cytotoxic agent represented by D and J CB a linker of a group; and

[0455] D is a cytotoxic agent covalently linked to the group L.

[0456] In one embodiment, J CB A thiol-reactive group.

[0457] Certain embodiments and specific embodiments of the first and second aspects of the present invention are described below.

[0458] In the first embodiment, for the conjugate of formula (I) in the first aspect of the present invention, J CB 'for

[0459]

[0460] wherein s1 is a site for covalent attachment to a cysteine ​​residue of an antibody, and s2 is a site for covalent attachment to a group L; and R a , R b , R c and R e is independently H or optionally substituted alkyl at each occurrence; and the remaining variables are as described above for Formula (I). In a specific embodiment, R a , R b , R c and R e H or C independently at each occurrence 1-3 In another specific embodiment, R a , R b , R c and R e All are H.

[0461] In the first embodiment, for the compound of formula (II) in the second aspect of the present invention, J CB for X'-CR b R c -C(=O)-, X'-CR b R c -C(=O)-NR e -、 R a , R b , R c and R eis independently at each occurrence H or optionally substituted alkyl; and the remaining variables are as described above for Formula (II).

[0462] In the second embodiment, for the conjugate of formula (I) in the first aspect of the present invention, J CB 'for wherein s1 is a site for covalent attachment to a cysteine ​​residue of an antibody, and s2 is a site for covalent attachment to a group L; and R a , R b , R c and R e is independently H or optionally substituted alkyl at each occurrence; and the remaining variables are as described above for Formula (I) in the first embodiment. In a specific embodiment, R a , R b , R c and R e H or C independently at each occurrence 1-3 In another specific embodiment, R a , R b , R c and R e All are H.

[0463] In the second embodiment, for the compound of formula (II) in the second aspect of the present invention, J CB for X'-CR b R c -C(=O)-, X'-CR b R c -C(=O)-NR e -、 R a , R b , R c and R e is independently at each occurrence H or optionally substituted alkyl; and the remaining variables are as described above for Formula (II) in the first embodiment.

[0464] In the third embodiment, for the conjugate of formula (I) in the first aspect of the present invention, J CB 'for and the remaining variables are as described above for formula (I).

[0465] In the third embodiment, for the compound of formula (II) in the second aspect of the present invention, J CB 'for and the remaining variables are as described above for formula (II).

[0466] In the fourth embodiment, for the conjugate of formula (I) of the first aspect of the present invention and the compound of formula (II) of the second aspect of the present invention, -L- is represented by the following structural formula:

[0467]

[0468] in:

[0469] S3 is covalently linked to J CB 'The site of the group, and s4 is the site covalently linked to the group D;

[0470] E is -(CR 10 R 11 ) q -, cycloalkyl or cycloalkylalkyl;

[0471] Z does not exist, is -SO2NR9-, -NR9SO2-, -C(=O)-NR9-, -NR9-C(=O)-, -C(=O)-O-, -OC(=O)-, -C(=O)-NR9-(CH2CH2O) p -、-NR9-C(=O)-(CH2CH2O) p -、-(OCH2CH2) p -C(=O)NR9- or -(OCH2CH2) p -NR9-C(=O)-;

[0472] p is an integer from 1 to 24;

[0473] Q is H, a charged substituent or an ionizable group;

[0474] R9, R 10 , R 11 , R 12 and R 13 is independently at each occurrence H or optionally substituted alkyl; and

[0475] q and r are independently integers between 0 and 10 at each occurrence.

[0476] The remaining variables in formula (I) or formula (II) are as described above in the first, 1st, 2nd or 3rd embodiment, or any other specific embodiment described therein.

[0477] In a particular embodiment, q and r are independently integers from 1 to 6, more specifically from 1 to 3.

[0478] In another specific embodiment, R9, R 10 , R 11 , R12 and R 13 H or C independently at each occurrence 1-3 More specifically, R9, R 10 , R 11 , R 12 and R 13 All are H.

[0479] In another specific embodiment, p is an integer from 2 to 14. More specifically, p is an integer from 2 to 8, 2 to 6, or 2 to 4.

[0480] In a specific embodiment, E is -(CR 10 R 11 ) q -; and the remaining variables in formula (L1) are as described above in the fourth embodiment.

[0481] In another specific embodiment, E is And the remaining variables in formula (L1) are as described above in the fourth embodiment.

[0482] In yet another specific embodiment, Z is -C(=O)-NR9- or -NR9-C(=O)-; and the remaining variables in formula (L1) are as described above in the fourth embodiment or any other specific embodiment described above. Even more specifically, R9 is H or Me. Alternatively, R9 is H.

[0483] In yet another specific embodiment, Q is i) H; ii) -SO3H, -Z'-SO3H, -OPO3H2, -Z'-OPO3H2, -PO3H2, -Z'-PO3H2, -CO2H, -Z'-CO2H, -NR 14 R 15 or -Z'-NR 14 R 15 or a pharmaceutically acceptable salt thereof; or iii) -N + R 14 R 15 R 16 X-or-Z'-N + R 14 R 15 R 16 X - ; Z' is an optionally substituted alkylene group, an optionally substituted cycloalkylene group or an optionally substituted phenylene group; R 14 To R 16 are each independently optionally substituted alkyl; and X -is a pharmaceutically acceptable anion; and the remaining variables in formula (L1) are as described above in the fourth embodiment or any other specific embodiment described above. In one embodiment, Z' is an optionally substituted alkylene. In yet another embodiment, Z' is a C1-3 alkylene (e.g., -CH2); and R 14 To R 16 Each independently is C 1-4 alkyl.

[0484] In yet another specific embodiment, Q is H or -SO3M, wherein M is a pharmaceutically acceptable cation (e.g., H + 、Na + or K + ); and the remaining variables in formula (L1) are as described above in the 4th embodiment or any other specific embodiment described above.

[0485] In the fifth embodiment, for the conjugate of formula (I) of the first aspect of the present invention, -J CB '-L- is represented by any of the following structural formulas:

[0486]

[0487] wherein q and r are each independently an integer from 1 to 6; M is a pharmaceutically acceptable cation; and the remaining variables are as described above for Formula (I). More specifically, q and r are each independently an integer from 1 to 3. In another more specific embodiment, M is H + 、Na + or K + .

[0488] Furthermore, in the fifth embodiment, for the compound of formula (II) of the second aspect of the present invention, J CB -L- is represented by any of the following structural formulas:

[0489]

[0490] wherein q and r are each independently an integer from 1 to 6; M is a pharmaceutically acceptable cation; and the remaining variables are as described above for Formula (II). More specifically, q and r are each independently an integer from 1 to 3. In another more specific embodiment, M is H + 、Na + or K + .

[0491] In the sixth embodiment, for the conjugate of formula (I) in the first aspect, -J CB '-L- is represented by any of the following structural formulas:

[0492]

[0493]

[0494] wherein M is a pharmaceutically acceptable cation and the remaining variables are as described above for Formula (I). More specifically, M is H + 、Na + or K + .

[0495] In addition, in the sixth embodiment, for the compound of formula (I) in the second aspect, J CB -L- is represented by any of the following structural formulas:

[0496]

[0497] wherein M is a pharmaceutically acceptable cation and the remaining variables are as described above for Formula (II). More specifically, M is H + 、Na + or K + .

[0498] In a seventh specific embodiment, for the conjugate of formula (I) in the first aspect and the compound of formula (II) in the second aspect, -L- is represented by the following structural formula:

[0499]

[0500] in:

[0501] S3 is covalently linked to J CB 'The site of the group, and s4 is the site covalently linked to the group D;

[0502] R 19 To R 22 is independently at each occurrence H or optionally substituted alkyl;

[0503] m and n are each independently an integer between 0 and 10;

[0504] R h is H or optionally substituted alkyl;

[0505] P is an optionally substituted alkylene group, -(CH2-CH2-O) j -、-(O-CH2-CH2) j -, amino acid residues or a peptide containing 2-20 amino acid residues; and

[0506] j is an integer from 1 to 24;

[0507] and the remaining variables are as described above for Formula (I) or Formula (II), the 1st, 2nd or 3rd embodiment, or any other specific embodiment described therein.

[0508] In an eighth embodiment, for formula (L2), R 19 , R 20 , R 21 and R 22 Each is H or C 1-3 alkyl; m and n are each independently an integer between 1 and 6; and the remaining variables are as described above in the seventh embodiment. More specifically, R 19 , R 20 , R 21 and R 22 are all H. Even more specifically, R 19 , R 20 , R 21 and R 22 are all H; and m and n are each independently an integer between 1 and 3.

[0509] In a ninth specific embodiment, for formula (L2), P is an amino acid residue or a peptide containing 2 to 10 amino acid residues; and the remaining variables are as described above in the seventh or eighth embodiment. More specifically, P is a peptide containing 2 to 5 amino acid residues.

[0510] In one embodiment, each amino acid residue is the residue of an amino acid independently selected from the group consisting of a naturally occurring amino acid, a synthetic amino acid, an amino acid analog, and an amino acid mimetic that functions in a manner similar to the naturally occurring amino acids.

[0511] In another embodiment, each amino acid residue is a residue of an amino acid independently selected from the group consisting of histidine, alanine, isoleucine, arginine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, glycine, valine, proline, serine, tyrosine, N-methyl-histidine, N-methyl-alanine, N-methyl-isoleucine, N-methyl-arginine, N-methyl-leucine, N-methyl-asparagine, N-methyl-lysine, N-methyl-aspartic acid, N-methyl-methionine, N-methyl-cysteine, N-methyl-phenylalanine, N-methyl-glutamic acid, N-methyl-threonine, The amino acid residues are selected from the group consisting of amino acids 1-(4-(dimethylamino)amino)-1-(4-nitropropionic acid) and 1-(4-nitropropionic acid). The amino acid residues are selected from the group consisting of amino acids 1-(4-(dimethylamino)amino)-1-(4-nitropropionic acid) and 1-(4-nitropropionic acid). The amino acid residues are selected from the group consisting of amino acids 1-(4-(dimethylamino)amino)-1-(4-nitropropionic acid) and 1-(4-nitropropionic acid).

[0512] In another embodiment, P is a peptide cleavable by a protease. More specifically, P is a peptide cleavable by a protease expressed in tumor tissue. Alternatively, P is a peptide cleavable by a lysosomal protease.

[0513] In yet another embodiment, P is selected from the group consisting of Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Trp, Cit, Phe-Ala, Phe-N 9 -Tosyl-Arg, Phe-N 9- Nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala-Leu (SEQ ID NO: 14), β-Ala-Leu-Ala-Leu (SEQ ID NO: 15), Gly-Phe-Leu-Gly (SEQ ID NO: 16), Val-Arg, Arg-Val, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-A la, Ala-D-Ala, D-Ala-Ala and D-Ala-D-Ala, Gly-Gly-Gly, Ala-Ala-A1a, D-A1a-A1a-Ala, A1a-D-Ala-Ala, Ala-Ala-D-Ala, Ala-Val-Cit, Ala-Val-Ala and β-Ala-Gly-Gly-Gly. More specifically, P is Gly-Gly-Gly, Ala-Ala-Ala, D-Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Val-Ala or β-Ala-Gly-Gly-Gly.

[0514] In the tenth embodiment, for the conjugate of formula (I) in the first aspect, -J CB '-L- is represented by the following structural formula:

[0515]

[0516] and the remaining variables are as described above for formula (I).

[0517] In addition, in the tenth embodiment, for the compound of formula (II) in the second aspect, J CB -L- is represented by the following structural formula:

[0518]

[0519] and the remaining variables are as described above for formula (II).

[0520] In the 11th embodiment, for the conjugate of formula (I) and the compound of formula (II), -L- is represented by the following structural formula:

[0521]

[0522] in:

[0523] S3 is covalently linked to J CB ', and s4 is a site covalently linked to D;

[0524] R 23 and R 24 is independently at each occurrence H or optionally substituted alkyl;

[0525] m' is an integer between 0 and 10; and

[0526] R h’ is H or optionally substituted alkyl;

[0527] and the remaining variables are as described above for Formula (I) or Formula (II), the 1st, 2nd or 3rd embodiment, or any specific embodiment described therein.

[0528] In a particular embodiment, m' is an integer from 1 to 6. Even more particularly, m' is an integer from 1 to 3.

[0529] In another specific embodiment, R 23 and R 24 H or C independently at each occurrence 1-3 alkyl. Even more specifically, R 23 With R 24 Both are H.

[0530] In another specific embodiment, R h ' is H or C 1-3 More specifically, R h 'For H.

[0531] In another specific embodiment, R 23 With R 24 are all H; m' is an integer from 1 to 6. Even more specifically, m' is an integer from 1 to 3.

[0532] In the twelfth embodiment, for the conjugate of formula (I) in the first aspect, -J CB '-L- is represented by the following structural formula:

[0533]

[0534] and the remaining variables are as described above for formula (I).

[0535] In addition, in the 12th embodiment, for the compound of formula (II) in the second aspect, J CB -L- is represented by the following structural formula:

[0536]

[0537] and the remaining variables are as described above for formula (II).

[0538] In another embodiment, for a conjugate of formula (I) or a compound of formula (II), the cytotoxic agent represented by D is maytansinoid; and the remaining variables are as described for formula (I) or (II), any of the 1st to 12th embodiments described above, or any other specific embodiment described therein.

[0539] In another embodiment, for the conjugate of formula (I) or the compound of formula (II), the cytotoxic agent represented by D is a benzodiazepine; and the remaining variables are as described for formula (I) or (II), any of the 1st to 12th embodiments described above, or any other specific embodiment described therein.

[0540] In the 13th embodiment, for the conjugate of formula (I) or the compound of formula (II), D is a maytansine represented by the following structural formula:

[0541]

[0542] in:

[0543] R M , R M ' and R M ” is independently at each occurrence H or optionally substituted alkyl;

[0544] R1', R2', R3' and R4' are independently at each occurrence H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0545] i is an integer between 0 and 15;

[0546] and the remaining variables are as described above for Formula (I) or Formula (II), any of the 1st to 10th embodiments described above, or any specific embodiment described therein.

[0547] More specifically, D is represented by the following structural formula:

[0548]

[0549] wherein i is 1 or 2; and R1' and R2' are each independently H or C 1-3 alkyl; and the remaining variables are as described in the thirteenth embodiment.

[0550] In a 14th specific embodiment, for the conjugate of formula (I) or the compound of formula (II), D is a maytansine represented by the following structural formula:

[0551]

[0552] and the remaining variables are as described above for Formula (I) or Formula (II), any of the 1st to 10th embodiments described above, or any specific embodiment described therein.

[0553] In the 15th embodiment, for the conjugate of formula (I) or the compound of formula (II), D is represented by the following structural formula:

[0554]

[0555]

[0556] or a pharmaceutically acceptable salt thereof, wherein:

[0557] Double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is selected from -H or an amine protecting group (preferably X is -H); and Y is selected from -OR, -OCOR', -SR, -NR'R", -SO3M, -SO2M or -OSO3M, wherein M is -H or a cation (such as Na + or K + );

[0558] R is -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or a PEG group -(CH2CH2O) n -R c , wherein n is an integer from 1 to 24, and R c is a straight or branched chain alkyl group having 1 to 4 carbon atoms;

[0559] R' and R" are each independently selected from -H, -OH, -OR, -NRR g’ , -COR, an optionally substituted linear, branched or cyclic alkyl group having 1 to 10 carbon atoms, an optionally substituted aryl group having 6 to 18 carbon atoms, an optionally substituted 3 to 18-membered heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N and P, a PEG group -(CH2CH2O) n -R c , and R g’ is -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or a PEG group -(CH2CH2O) n -R c;

[0560] X' is selected from the group consisting of: -H, -OH, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a phenyl group, and an amine protecting group;

[0561] Y' is selected from the group consisting of: -H, an oxo group, a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0562] A and A' are selected from -O- and -S-;

[0563] W' is absent or selected from -O-, -N(R e )-、-N(R e )-C(=O)-, -N(C(=O)R e )-、-S- or -CH2-S-、-CH2NR e -;

[0564] R x Absent or selected from linear, branched or cyclic alkyl groups having 1 to 10 carbon atoms;

[0565] R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or -(CH2-CH2-O) n -R k , where R k is -H, a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, optionally carrying a secondary amino group (e.g., -NHR 101 ) or tertiary amino group (-NR 101 R 102 ) or a 5- or 6-membered nitrogen-containing heterocycle (such as piperidine or morpholine), wherein R 101 and R 102 Each is independently a straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0566] G is selected from -CH- or -N-; and

[0567] R6 is -H, -R, -OR, -SR, -NR'R", -NO2 or halogen;

[0568] and the remaining variables are as described above for Formula (I) or Formula (II), any of the 1st to 10th embodiments, or any specific embodiments described therein.

[0569] In a specific embodiment, D is represented by the above formula (IBD1), or a pharmaceutically acceptable salt thereof.

[0570] In another specific embodiment, for Formula (IBD1)-(IBD6):

[0571] Double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -OH or -SO3M;

[0572] M is -H or a pharmaceutically acceptable cation (e.g., Na + );

[0573] X' and Y' are both -H;

[0574] A and A' are both -O-;

[0575] R6 is -OMe; and

[0576] R x is a straight chain or branched chain alkyl group having 1 to 6 carbon atoms.

[0577] In the 16th embodiment, for the conjugate of formula (I) or the compound of formula (II), D is represented by the following structural formula:

[0578]

[0579]

[0580] or a pharmaceutically acceptable salt thereof, wherein the double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -OH or -SO3M; and the remaining variables are as described above for formula (I) or (II), any one of the 1st to 10th embodiments, or any specific embodiment described therein.

[0581] In a specific embodiment, for the above formulas (IBD7)-(IBD10) and (IBD7a) and (IBD9a), Y is -SO3M; and M is H + 、Na + or K + .

[0582] In the 17th embodiment, for the conjugate of formula (I) or the compound of formula (II), D is represented by the following structural formula:

[0583]

[0584] or a pharmaceutically acceptable salt thereof, wherein:

[0585] One of L', L", and L'' is represented by the following formula:

[0586] -Z1-P1-Z2-R x1 -C(=O)-(A'), or

[0587] -N(R e )-R x1 -C(=O)-(D′);

[0588] The other two are each independently selected from -H, an optionally substituted straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c , halogen, guanidine [-NH(C=NH)NH2], -OR, -NR'R", -NO2, -NR'COR", -SR, -SOR', -SO2R', -SO3H, -OSO3H, -SO2NR'R", cyano, azido, -COR', -OCOR', and -OCONR'R";

[0589] One of Z1 and Z2 is -C(=O)-, and the other is -NR5-;

[0590] P1 is an amino acid residue or a peptide containing 2 and 20 amino acid residues;

[0591] R x1 is an optionally substituted straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0592] R e is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, or -(CH2-CH2-O) n -R k , where R k is -H, a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, optionally carrying a secondary amino group (e.g., -NHR 101 ) or tertiary amino group (-NR 101 R 102 ) or a 5- or 6-membered nitrogen-containing heterocycle (such as piperidine or morpholine), wherein R 101 and R 102 Each is independently a straight chain, branched chain or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms;

[0593] Double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X1 is absent and Y1 is -H or a straight or branched chain alkyl group having 1 to 4 carbon atoms, and when it is a single bond, X1 is -H or an amine protecting moiety; and Y1 is a leaving group selected from the group consisting of -OR, -OCOR', -OCOOR', -OCONR'R", -NR'R", -NR'COR", -NR'NR'R", an optionally substituted 5- or 6-membered nitrogen-containing heterocycle (e.g., piperidine, tetrahydropyrrole, or the like attached via a nitrogen atom). , pyrazole, morpholine, etc.), guanidine represented by -NR'(C=NH)NR'R", amino acid or peptide represented by -NRCOP', -SR, -SOR', halogen, cyano, azido, -OSO3H (or its salt), sulfite (-SO3H or -SO2H or its salt), metabisulfite (H2S2O5 or its salt), mono-, di-, tri- and tetra-thiophosphate (PO3SH3, PO2S2H2, POS3H2, PS4H2 or its salt), thiophosphate (R i O)2PS(OR i ), R i S-, R i SO, R i SO2、R i SO3, thiosulfate (HS2O3 or its salt), dithionite (HS2O4 or its salt), dithiophosphate (P(=S)(OR k’ )(S)(OH) or its salt), hydroxamic acid (R k’ C(=O)NOH or its salt) and formaldehyde sulfoxylate (HOCH2SO2 - or its salt) or a mixture thereof, wherein R i is a straight or branched alkyl group having 1 to 10 carbon atoms and is substituted with at least one selected from -N(R j )2, -Co2H, -SO3H and -PO3H; R i may be further optionally substituted with alkyl substituents as described herein; R j is a straight or branched chain alkyl group having 1 to 6 carbon atoms; R k’ is a linear, branched or cyclic alkyl, alkenyl or alkynyl, aryl, heterocyclic or heteroaryl group having 1 to 10 carbon atoms;

[0594] P' is an amino acid residue or a peptide containing 2 to 20 amino acid residues,

[0595] R is independently selected at each occurrence from the group consisting of: -H, optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, polyethylene glycol unit -(CH2CH2O) n -R c, an optionally substituted aryl group having 6 to 18 carbon atoms, an optionally substituted 5 to 18 membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, or an optionally substituted 3 to 18 membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P;

[0596] R' and R" are each independently selected from -H, -OH, -OR, -NHR, -NR2, -COR, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c and optionally substituted 3 to 18 membered heterocyclic rings having 1 to 6 heteroatoms independently selected from O, S, N and P;

[0597] R c is -H or an optionally substituted straight or branched chain alkyl group having 1 to 4 carbon atoms;

[0598] n is an integer from 1 to 24;

[0599] Xx' is selected from -H, an amine protecting group, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c , optionally substituted aryl having 6 to 18 carbon atoms, optionally substituted 5 to 18 membered heteroaryl rings containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, and optionally substituted 3 to 18 membered heterocyclic rings containing 1 to 6 heteroatoms independently selected from O, S, N and P;

[0600] Y1' is selected from -H, oxo, optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, optionally substituted 6 to 18 membered aryl, optionally substituted 5 to 18 membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur, optionally substituted 3 to 18 membered heterocyclic ring having 1 to 6 heteroatoms;

[0601] R1, R2, R3, R4, R1', R2', R3' and R4' are each independently selected from the group consisting of: -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl group having 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O) n -R c , halogen, guanidine [-NH(C=NH)NH2], -OR, -NR'R", -NO2, -NCO, -NR'COR", -SR, -SOR', -SO2R', -SO3 -H, -OSO3H, -SO2NR'R", cyano, azido, -COR', -OCOR', and -OCONR'R";

[0602] R6 is -H, -R, -OR, -SR, -NR'R", -NO2 or halogen;

[0603] G is -CH- or -N-;

[0604] A and A' are the same or different and are independently selected from -O-, oxo (-C(=O)-), -CRR'O-, -CRR'-, -S-, -CRR'S-, -NR5 and -CRR'N(R5)-; and

[0605] R5, at each occurrence, is independently -H or an optionally substituted straight or branched chain alkyl group having 1 to 10 carbon atoms;

[0606] and the remaining variables are as described for formula (I) or (II), the 1st, 2nd, 3rd, 11th or 12th specific embodiment, or any other specific embodiment described therein.

[0607] In a more specific embodiment, D is represented by formula (IBD11).

[0608] In another more specific embodiment, for formula (IBD11)-(IBD16), one of L', L" and L'" is represented by formula (A') or (D'), and the rest are -H, a straight chain or branched alkyl group having 1 to 6 carbon atoms, halogen, -OH, (C1-C6) alkoxy or -NO2.

[0609] In another more specific embodiment, for Formulas (IBD11)-(IBD16), L' is represented by Formula (A'); and L" and L'" are both -H.

[0610] In another more specific embodiment, for Formulas (IBD11)-(IBD16), L' is represented by Formula (D'); and L" and L'" are both -H.

[0611] In another more specific embodiment, for Formula (IBD11)-(IBD16), R xl It is a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms or a charged substituent or ionizable group Q which is optionally substituted with halogen, -OH, -SO3H, (C1-C3)alkyl, (C1-C3)alkoxy, or halo(C1-C3)alkyl.

[0612] In an 18th specific embodiment, for Formula (IBD11)-(IBD16), L' is represented by the following formula:

[0613] -NR5-P1-C(=O)-(CR a R b ) s -C(=O)-(B1′);

[0614] -NR5-P1-C(=O)-Cy-(CR a R b ) s1’ -C(=O)-(B2');

[0615] -C(=O)-P1-NR5-(CR a R b ) s -C(=O)-(C1′), or

[0616] -C(=O)-P1-NR5-Cy-(CR a R b ) s1’ -C(=O)-(C2')

[0617] in:

[0618] R a and R b Each occurrence is independently -H, (C1-C3)alkyl, or a charged substituent or ionizable group Q;

[0619] s is an integer from 1 to 6;

[0620] s1' is 0 or an integer from 1 to 6; and

[0621] Cy is a cyclic alkyl group having 5 or 6 ring carbon atoms which is optionally substituted with halogen, -OH, (C1-C3)alkyl, (C1-C3)alkoxy or halo(C1-C3)alkyl;

[0622] And the remaining variables are as described above in the 17th specific embodiment or any other specific embodiment described therein.

[0623] In a more specific embodiment, R a With R b are H; Cy in formula (B2') and (C2') is cyclohexane; and R5 is H or Me. Even more specifically, s1' is 0 or 1.

[0624] In a 19th embodiment, for formula (IBD11)-(IBD16), P1 is a peptide containing 2 to 10 amino acid residues; and the remaining variables are as described in the 17th or 18th specific embodiment.

[0625] In a specific embodiment, P1 is a peptide containing 2 to 5 amino acid residues.

[0626] In another specific embodiment, P1 is Gly-Gly-Gly, Ala-Val, Val-Ala, Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Trp, Cit, Phe-Ala, Phe-N 9 -Tosyl-Arg, Phe-N 9 - Nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala-Leu (SEQ ID NO: 14), β-Ala-Leu-Ala-Leu (SEQ ID NO: 15), Gly-Phe-Leu-Gly (SEQ ID NO: 16), Val-Arg, Arg-Val, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-D-Ala, Ala-Met or Met-Ala. Even more specifically, P is Gly-Gly-Gly, Ala-Val, Ala-Ala, Ala-D-Ala, D-Ala-Ala or D-Ala-D-Ala.

[0627] In the 20th embodiment, for formula (IBD11)-(IBD16), the double linear represents a double bond; and the remaining variables are as described above in the 17th, 18th or 19th embodiment.

[0628] In the 21st embodiment, for formula (IBD11)-(IBD16), the double linear represents a single bond, X1 is -H or an amine protecting group; and Y1 is -OR, -OCOR', -SR, -NR'R", an optionally substituted 5- or 6-membered nitrogen-containing heterocycle, -SO3M, -SO2M or -OSO3M, wherein M is H +or a pharmaceutically acceptable cation; and the remaining variables are as described above in the 17th, 18th or 19th embodiment. Specifically, Y1 is selected from -SO3M, -OH, -OMe, -OEt or -NHOH. More specifically, Y1 is -SO3M or -OH, wherein M is H + 、Na + or K + .

[0629] In certain embodiments, Formula (IBD11)-(IBD16), X1' is selected from the group consisting of: -H, -OH, optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, and phenyl; and the remaining variables are as described above in the 17th, 18th, 19th, 20th or 21st specific embodiments. More specifically, X1' is -H, -OH, (C1-C3) alkyl, halo (C1-C3) alkyl or phenyl. In another more specific embodiment, X1' is -H, -OH or -Me. Even more specifically, X1' is -H.

[0630] In certain embodiments, for Formula (IBD11)-(IBD16), Y1' is selected from the group consisting of: -H, oxo, optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms; and the remaining variables are as described above in the 17th, 18th, 19th, 20th or 21st specific embodiments. More specifically, Y1' is -H, oxo, (C1-C3)alkyl or halo(C1-C3)alkyl. In another more specific embodiment, Y1' is -H or oxo. Even more specifically, Y1' is -H.

[0631] In certain embodiments, for Formula (IBD11)-(IBD16), A and A' are the same or different and are -O-, -S-, -NR5- or oxo-(C=O)-; and the remaining variables are as described above in the 17th, 18th, 19th, 20th or 21st specific embodiments. More specifically, A and A' are the same or different and are -O- and -S-. Even more specifically, A and A' are -O-.

[0632] In certain embodiments, for Formula (IBD11)-(IBD16), R6 is -OMe; and the remaining variables are as described above in the 17th, 18th, 19th, 20th or 21st embodiment.

[0633] In certain embodiments, for Formula (IBD11)-(IBD16), R1, R2, R3, R4, R1', R2', R3' and R4' are each independently -H, halogen, -NO2, -OH, (C1-C3) alkyl, halo (C1-C3) alkyl or (C1-C3) alkoxy; and the remaining variables are s as described. More specifically, R1, R2, R3, R4, R1', R2', R3' and R4' are all -H.

[0634] In certain embodiments, for Formula (IBD11)-(IBD16), R, R', R", and R5 are each independently -H or (C1-C3) alkyl; and the remaining variables are as described above in the 17th, 18th, 19th, 20th or 21st embodiment.

[0635] In a 22nd embodiment, for formula (IBD11)-(IBD16):

[0636] Double line between N and C represents a single bond or a double bond, with the restriction that when it is a double bond, X1 is absent and Y1 is -H; and when it is a single bond, X1 is -H and Y1 is -OH or -SO3M;

[0637] R1, R2, R3, R4, R1', R2', R3' and R4' are all -H;

[0638] R6 is -OMe;

[0639] X1' and Y1' are both -H;

[0640] A and A' are -O-; and

[0641] M is H + 、Na + or K + ; and the remaining variables are as described above in the 17th, 18th, 19th, 20th or 21st specific embodiments. More specifically, R, R', R" and R5 are each independently -H or (C1-C3) alkyl. Even more specifically, R, R', R" and R5 are all H.

[0642] In the 23rd embodiment, for the conjugate of formula (I) or the compound of formula (II), D is represented by the following structural formula:

[0643]

[0644]

[0645]

[0646] The double line between N and C represents a single bond or a double bond, with the restriction that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -SO3M; M is H + or a pharmaceutically acceptable cation thereof; and the remaining variables are as described above in the seventeenth embodiment.

[0647] In the 24th embodiment, for the conjugate of formula (I), the conjugate is represented by the following structural formula:

[0648]

[0649]

[0650]

[0651]

[0652]

[0653]

[0654]

[0655] or a pharmaceutically acceptable salt thereof, wherein the double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -SO3M; and M is H + or a pharmaceutically acceptable cation thereof. More specifically, M is H + 、Na + or K + .

[0656] In addition, in the 24th embodiment, for the compound of formula (II), the compound is represented by the following structural formula:

[0657]

[0658]

[0659]

[0660] or a pharmaceutically acceptable salt thereof, wherein the double line between N and C represents a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H, and when it is a single bond, X is -H and Y is -SO3M; and M is H + or a pharmaceutically acceptable cation thereof.

[0661] In the 25th embodiment, for the conjugate described in the first embodiment or any one of the 1st to 24th embodiments, w is 2. Alternatively, w is 1.

[0662] In certain embodiments, in any of the above embodiments, the charged substituent or ionizable group Q described is i) -SO3H, -Z'-SO3H, -OPO3H2, -Z'-OPO3H2, -PO3H2, -Z'-PO3H2, -CO2H, -Z'-CO2H, -NR 11 R 12 or -Z'-NR 11 R 12 or a pharmaceutically acceptable salt thereof; or ii) -N + R 14 R 15 R 16 X - or -Z'-N + R 14 R 15 R 16 X - ; Z' is an optionally substituted alkylene group, an optionally substituted cycloalkylene group or an optionally substituted phenylene group; R 14 To R 16 are each independently optionally substituted alkyl; and X - is a pharmaceutically acceptable anion. More specifically, Q is -SO3H or a pharmaceutically acceptable salt thereof.

[0663] In certain embodiments, the antibody in the conjugate of the invention is an antibody with an engineered cysteine ​​residue (e.g., at EU / OU numbering position 442 of the heavy chain). The engineered Cys residue may be located on one or both heavy chains of the antibody or one or both light chains of the antibody or its antigen-binding portion or a combination thereof. In one embodiment, the Cys residue is located at EU / OU numbering position 442 of the antibody heavy chain. In a certain embodiment, the antibody is a cysteine ​​engineered antibody as described herein.

[0664] In certain embodiments, the antibodies of the invention are monoclonal antibodies, chimeric antibodies, humanized antibodies, resurfaced antibodies, or human antibodies.

[0665] In other embodiments, the cell-binding agent is an antibody, a single chain antibody, an antibody fragment that specifically binds to a target cell; a monoclonal antibody, a single chain monoclonal antibody, a monoclonal antibody fragment (or "antigen-binding portion") that specifically binds to a target cell; a chimeric antibody, a chimeric antibody fragment (or "antigen-binding portion") that specifically binds to a target cell; a domain antibody (e.g., sdAb) or a domain antibody fragment that specifically binds to a target cell.

[0666] In certain embodiments, the cell binding agent is a humanized antibody, a humanized single-chain antibody, or a humanized antibody fragment (or "antigen binding portion"). In a specific embodiment, the humanized antibody is huMy9-6 or another related antibody described in U.S. Patent Nos. 7,342,110 and 7,557,189. In another specific embodiment, the humanized antibody is an anti-folate receptor antibody described in U.S. Patent No. 8,557,966. In another embodiment, the humanized antibody is an anti-CD123 antibody described in U.S. Provisional Application No. 62 / 186,161, entitled "ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVESTHEREOF", filed on June 29, 2015. The teachings of all these applications are incorporated herein by reference in their entirety.

[0667] In certain embodiments, the cell-binding agent is a resurfaced antibody, a resurfaced single chain antibody, a resurfaced antibody fragment (or "antigen-binding portion"), or a bispecific antibody.

[0668] Yet another aspect of the present invention provides a recombinant antibody comprising a mature processed sequence of a heavy chain, a light chain or an antigen binding portion thereof derived from any one of the heavy chains (HC), light chains (LC) or antigen binding portions thereof of the subject recombinant antibodies described herein.

[0669] For example, the recombinant antibody may be or may comprise scFv-Fc, Fcab, mAb2, small modular immunopharmaceutical (SMIP), Genmab / monobody or duobody, minibody, IgGΔCH2, DVD-Ig, probody, intrabody or multispecific antibody.

[0670] It is a bispecific modified IgG1 antibody heterodimer. The IgG1 hinge region generally includes (i) a stable hinge region, which contains a CPPC sequence and does not allow in vivo Fab arm exchange, and (ii) an IgG4-like CH3 domain, which is modified to contain F405L and K409R residues, which allows in vivo Fab arm exchange. (See, for example, WO2008119353 and WO2011131746).

[0671] In certain embodiments, the recombinant antibody may comprise 1, 2, 3 or 4 mature processing sequences of the heavy chain, light chain or antigen binding portion thereof, each of which is derived from any one of the subject recombinant antibody heavy chains (HC), light chains (LC) or antigen binding portions thereof described herein.

[0672] In certain embodiments, the recombinant antibody may be a heterodimeric antibody comprising a first heavy chain polypeptide and a second heavy chain polypeptide, wherein the Fc region of the first heavy chain polypeptide and the Fc region of the second heavy chain polypeptide meet at an interface, and the interface of the Fc region of the second heavy chain polypeptide comprises a protuberance that may be positioned in a cavity in the interface of the Fc region of the first heavy chain polypeptide. In certain embodiments, the knob-in-hole technology used to promote specific pairing of heavy chains in bispecific antibodies may be further improved based on, for example, the CrossMab technology of Genentech / Roche, for example, by exchanging the CH1 and kappa constant regions to further reduce or eliminate light chain mispairing.

[0673] Alternatively, similar results can be achieved using LC heterodimers in the development of fully bispecific antibodies, such as the Zymeworks AZYMETRIC TM Heterodimeric IgG1 light chain platform technology, including common light chain, domain antibodies and single chain formats.

[0674] In certain embodiments, the Fc region of the second heavy chain polypeptide has been altered relative to the template / original polypeptide to encode a knob, or the Fc region of the first heavy chain polypeptide has been altered relative to the template / original polypeptide to encode a cavity, or both.

[0675] In certain embodiments, the protuberances and valleys each comprise naturally occurring amino acid residues.

[0676] In certain embodiments, the knob-containing Fc region of the second heavy chain polypeptide is generated by replacing native residues at the template / native polypeptide interface with import residues having a larger side chain volume than the native residues.

[0677] In certain embodiments, the Fc region comprising a knob of a second heavy chain polypeptide is produced by a method comprising the steps of replacing nucleic acid encoding an original residue of the polypeptide interface with nucleic acid encoding an import residue having a larger side chain volume than the original residue.

[0678] In certain embodiments, the antibodies include bispecific, multispecific, and monospecific antibody variants comprising an antigen binding region and a heavy chain constant domain, wherein the heavy chain constant domain is modified to include Cys at position 442 of EU / OU numbering.

[0679] In certain embodiments, the antibody can bind to a ligand on a target cell, such as a cell surface ligand, including a cell surface receptor.

[0680] Specific exemplary antigens or ligands may include renin; growth hormone (e.g., human growth hormone and bovine growth hormone); growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoprotein; alpha-1-antitrypsin; insulin A chain; insulin B chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; coagulation factors (e.g., factor vmc, factor IX, tissue factor, and von Willebrands factor); anticoagulant factors (e.g., protein C); atrial natriuretic factor; pulmonary surfactant; plasminogen activators (e.g., urokinase, human urinary or tissue-type plasminogen activator); bombesin; thrombin; hematopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (i.e., factor expressed and secreted by activated normal T cells); human macrophage inflammatory protein-1-alpha; serum albumin (human serum albumin); Muellerian-inhibiting substance); relaxin A chain; relaxin B chain; prorelaxin; mouse gonadotropin-related peptide; microbial protein (β-lactamase); DNA enzyme; IgE; cytotoxic T lymphocyte-associated antigen (e.g., CTLA-4); inhibin; activin; vascular endothelial growth factor; hormone or growth factor receptor; protein A or D; rheumatoid factor; neurotrophic factor (e.g., bone-derived neurotrophic factor, neurotrophin-3, -4, -5, or -6); nerve growth factor (e.g., NGF-β); platelet-derived growth factor; fibroblast growth factor (e.g., aFGF and bFGF); fibroblast growth factor (e.g., growth factor receptor 2, epidermal growth factor; transforming growth factors (such as TGF-α, TGF-β1, TGF-β2, TGF-β3, TGF-β4 and TGF-β5); insulin-like growth factor-I and -II; des(1-3)-IGF-I (brain IGF-I); insulin-like growth factor binding protein, melanocyte transferrin, EpCAM, GD3, FLT3, PSMA, PSCA, MUC1, MUC16, STEAP, CEA, TENB2, EphA receptor, EphB receptor, folate receptor, FOLR1, mesothelin, teratoma-derived growth factor quercetin, α vβ6, integrin, VEGF, VEGFR, EGFR, transferrin receptor; IRTA1; IRTA2; IRTA3; IRTA4; IRTA5; CD proteins (e.g., CD2, CD3, CD4, CD5, CD6, CD8, CD11, CD14, CD19, CD20, CD21, CD22, CD25, CD26, CD28, CD30, CD33, CD36, CD37, CD38, C one or more tumor-associated antigens or cell surface receptors (see U.S. Publication No. 2008 / 0171040 or U.S. Publication No. 2008 / 0305044, which are incorporated herein by reference in their entirety); ; erythropoietin; osteogenic inductive factor; immunotoxin; bone morphogenic protein; interferon (e.g., interferon-α, -β and -γ); colony stimulating factor (e.g., M-CSF, GM-CSF and G-CSF; interleukins (e.g., IL-1 to IL-10); superoxide dismutase; T cell receptor; surface membrane protein; decay accelerating factor; viral antigen (e.g., a portion of the HIV envelope); transporter; homing receptor; addressin; regulatory protein; integrin (e.g., CD11a, CD11b, CD11c, CD18, ICAM, VLA-4 and VCAM); tumor associated antigens (e.g., HER2, HER3 and HER4 receptors); endothelin; c-Met; c-kit; 1GF1R; PSGR; NGEP; PSMA; PSCA; TMEFF2; LGR5; B7H4; and fragments of any of the polypeptides listed above.

[0681] In one embodiment, the cell binding agent is an anti-folate receptor antibody. More specifically, the anti-folate receptor antibody is a humanized antibody that specifically binds to human folate receptor 1, wherein the antibody comprises: (a) a heavy chain CDR1 comprising GYFMN (SEQ ID NO: 1); a heavy chain CDR2 comprising RIHPYDGDTFYNQXaa1FXaa2Xaa3 (SEQ ID NO: 2); and a heavy chain CDR3 comprising YDGSRAMDY (SEQ ID NO: 3); and (b) a light chain CDR1 comprising KASQSVSFAGTSLMH (SEQ ID NO: 4); a light chain CDR2 comprising RASNLEA (SEQ ID NO: 5); and a light chain CDR3 comprising QQSREYPYT (SEQ ID NO: 6). NO: 6); wherein Xaa1 is selected from K, Q, H and R; Xaa2 is selected from Q, H, N and R; and Xaa3 is selected from G, E, T, S, A and V. Preferably, the heavy chain CDR2 sequence comprises RIHPYDGDTFYNQKFQG (SEQ ID NO: 7).

[0682] In another embodiment, the anti-folate receptor antibody is a humanized antibody or an antigen-binding fragment thereof that specifically binds to human folate receptor 1, wherein the humanized antibody or the antigen-binding fragment thereof comprises a heavy chain having the following amino acid sequence:

[0683] In another embodiment, the anti-folate receptor antibody is a humanized antibody or an antigen-binding fragment thereof that specifically binds to human folate receptor 1, wherein the humanized antibody or the antigen-binding fragment thereof comprises a light chain having the following amino acid sequence:

[0684] In another embodiment, the anti-folate receptor antibody is a humanized antibody or an antigen-binding fragment thereof that specifically binds to human folate receptor 1, wherein the humanized antibody or the antigen-binding fragment thereof comprises a heavy chain having an amino acid sequence of SEQ ID NO: 8 and a light chain having an amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10. Preferably, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO: 8 and a light chain having an amino acid sequence of SEQ ID NO: 10 (huMov19).

[0685] In another embodiment, the anti-folate receptor antibody is a humanized antibody or antigen-binding fragment thereof comprising an engineered Cys residue (e.g., C442) and a heavy chain variable domain at least about 90%, 95%, 99% or 100% identical to the following sequence: QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS (SEQ ID NO: 11); and a light chain variable domain that is at least about 90%, 95%, 99% or 100% identical to the following sequence: DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLNISPVEAEDAATYYCQQSREYPYTFGGGTKLEIKR (SEQ ID NO: 12); or DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIKR (SEQ ID NO: 13).

[0686] In a specific embodiment, the humanized antibody is huMy9-6 or another related antibody described in U.S. Patent Nos. 7,342,110 and 7,557,189. In another specific embodiment, the humanized antibody is an anti-folate receptor antibody (e.g., huMov19) described in U.S. Patent No. 8,577,966. In certain embodiments, the humanized antibody is an anti-CD37 antibody (e.g., anti-CD37-3) described in U.S. Patent No. 8,765,917. In certain embodiments, the humanized antibody is an anti-EGFR antibody described in U.S. Patent No. 8,790,649. In another embodiment, the antibody is an anti-EGFR antibody. In one embodiment, the anti-EGFR antibody is a non-antagonist antibody, including, for example, an antibody described in WO2012058592, which is incorporated herein by reference. In another embodiment, the anti-EGFR antibody is a non-functional antibody, for example, humanized ML66. More specifically, the anti-EGFR antibody is huML66.

[0687] In one embodiment, the antibody is an anti-CD123 antibody, such as a humanized huCD123 antibody as described in U.S. Provisional Application No. 62 / 186,161, filed June 29, 2015, entitled “ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF,” the entire contents of which, including all sequences and drawings, are incorporated herein.

[0688] Method for preparing the conjugate of the present invention

[0689] The above-described immunoconjugates (e.g., immunoconjugates of formula (I) or any of the first to twenty-fifth embodiments or any specific embodiments described therein) can be prepared by reacting an antibody having one or more free cysteines with a compound having a thiol-reactive group as described herein.

[0690] In one embodiment, the compound having a thiol-reactive group is represented by formula (II) or a compound of any one of the first through twenty-fifth embodiments or any specific embodiments described therein.

[0691] In certain embodiments, an organic solvent is used to dissolve the compound in the reaction of CBA with a thiol-reactive group. Exemplary organic solvents include, but are not limited to, dimethylacetamide (DMA), propylene glycol, and the like. In one embodiment, the reaction of CBA with the compound is carried out in the presence of DMA and propylene glycol.

[0692] Compositions and methods of use

[0693] The present invention includes a composition (e.g., a pharmaceutical composition) comprising a novel benzodiazepine compound (e.g., indolinone benzodiazepine or oxazolidinone benzodiazepine), a derivative thereof, or a conjugate thereof (and / or a solvate, hydrate, and / or salt thereof) and a carrier (a pharmaceutically acceptable carrier) as described herein. The present invention also includes a composition (e.g., a pharmaceutical composition) comprising a novel benzodiazepine compound, a derivative thereof, or a conjugate thereof (and / or a solvate, hydrate, and / or salt thereof) and a carrier (a pharmaceutically acceptable carrier) as described herein, further comprising a second therapeutic agent. The composition of the present invention can be used to inhibit abnormal cell growth or treat a proliferative disorder in a mammal (e.g., a human). The present invention includes a method of inhibiting abnormal cell growth or treating a proliferative disorder in a mammal (e.g., a human), the method comprising administering to the mammal a therapeutically effective amount of a therapeutic agent or composition, alone or in combination with a second therapeutic agent, such as a novel benzodiazepine compound (e.g., an indolinobenzodiazepine or an oxazolidinonebenzodiazepine), a derivative thereof, or a conjugate thereof (and / or a solvate and salt thereof), or a combination thereof, described herein.

[0694] In one embodiment, the proliferative disorder is cancer. The cancer may include a hematological cancer or a solid tumor. More specifically, the cancer is a leukemia (e.g., acute myeloid leukemia (AML)), an acute lymphoblastic leukemia (ALL) such as acute B-lymphoblastic leukemia (B-ALL), a chronic myeloid leukemia (CML), a chronic lymphocytic leukemia (CLL) or a lymphoma, a melanoma, a lung cancer (e.g., non-small cell lung cancer), an ovarian cancer, an endometrial cancer, a peritoneal cancer, a pancreatic cancer, a breast cancer, a prostate cancer, and a cervical cancer.

[0695] The present invention also provides a method of treatment, which comprises administering an effective amount of any one of the above-mentioned combinations to a subject in need of treatment.

[0696] Similarly, the present invention provides a method for inducing cell death of a selected cell population, the method comprising contacting a target cell or a tissue containing a target cell with an effective amount of a cytotoxic agent, the cytotoxic agent comprising any one of the cytotoxic compounds-cell binding agents of the present invention (e.g., an indolinobenzodiazepine or oxazolidinonebenzodiazepine dimer linked to a cell binding agent), a salt or solvate thereof. The target cell is a cell to which the cell binding agent can bind.

[0697] If desired, other active agents (such as other anti-tumor agents) can be administered together with the combination.

[0698] Suitable pharmaceutically acceptable carriers, diluents and excipients are well known and can be determined by those skilled in the art as the clinical situation permits. Examples of suitable carriers, diluents and / or excipients include: (1) Dulbecco's phosphate buffered saline, pH about 7.4, containing about 1 mg / mL to 25 mg / mL human serum albumin or no human serum albumin; (2) 0.9% saline (0.9% w / v NaCl); and (3) 5% (w / v) dextrose; and may also contain antioxidants, such as tryptamine; and stabilizers, such as Tween 20.

[0699] Methods of inducing cell death in a selected cell population can be practiced in vitro, in vivo, or ex vivo.

[0700] Examples of in vitro use include treating autologous bone marrow before transplantation into the same patient to kill diseased or malignant cells; treating it before bone marrow transplantation to kill competent T cells and prevent graft-versus-host disease (GVHD); treating cell cultures to kill all cells except for the desired variant that does not express the target antigen; or killing variants that express undesired antigens. Conditions for non-clinical in vitro use can be readily determined by those skilled in the art.

[0701] An example of clinical ex vivo use is to remove tumor cells or lymphocytes from the bone marrow before autologous transplantation in cancer treatment or autoimmune disease treatment, or to remove T cells and other lymphocytes from autologous or allogeneic bone marrow or tissue before transplantation to prevent GVHD. Treatment can be performed as follows. Bone marrow is collected from a patient or other individual, and then incubated at about 37°C in a serum-containing medium with a concentration of a cytotoxic agent of the present invention in the range of about 10 μM to 1 pM for about 30 minutes to about 48 hours. The exact conditions for incubation concentration and time (i.e., dosage) can be easily determined by a person skilled in the art. After incubation, the bone marrow cells are washed with a serum-containing medium and are intravenously infused back to the patient according to known methods. In the case where the patient receives other treatments (such as radical chemotherapy or a course of whole body irradiation) between bone marrow collection and the time of treated cell infusion, the treated bone marrow cells are frozen and stored in liquid nitrogen using standard medical equipment.

[0702] For clinical in vivo use, the cytotoxic agents of the invention will be provided in the form of solutions or lyophilized powders tested for sterility and endotoxin levels. Specific clinical protocols regarding routes of administration, excipients, diluents, dosages, time, etc. can be determined by those skilled in the art as the clinical situation permits.

[0703] Examples of medical conditions that can be treated according to in vivo or ex vivo methods of inducing cell death in a selected cell population include any type of malignant disease, including, for example, cancer; autoimmune diseases, such as systemic lupus, rheumatoid arthritis, and multiple sclerosis; transplant rejection, such as kidney transplant rejection, liver transplant rejection, lung transplant rejection, heart transplant rejection, and bone marrow transplant rejection; graft-versus-host disease; viral infections, such as CMV infection, HIV infection, AIDS, etc.; and parasitic infections, such as giardiasis, amoebiasis, schistosomiasis, and other diseases as determined by those skilled in the art.

[0704] The specific clinical regimen regarding administration routes, excipients, diluents, dosages, time, etc. can be determined by those skilled in the art as the clinical situation permits.

[0705] Cancer therapies and their dosages, routes of administration, and recommended uses are known in the art and are described in documents such as the Physician's Desk Reference (PDR). The PDR discloses dosages of agents that have been used to treat various cancers. The dosage regimen and dosage of these chemotherapeutic drugs that are therapeutically effective will depend on the specific cancer being treated, the extent of the disease, and other factors familiar to a skilled physician in the art, and can be determined by the physician. The contents of the PDR are expressly incorporated herein by reference in their entirety. One skilled in the art may review the PDR using one or more of the following parameters to determine the dosage regimen and dosage of chemotherapeutic agents and conjugates that may be used in accordance with the teachings of the present invention. These parameters include:

[0706] Comprehensive indicators

[0707] Provided by the manufacturer

[0708] Product (by company or branded drug name)

[0709] Category Index

[0710] Generic / Chemical Index (non-trademark common drug names)

[0711] Color images of drugs

[0712] FDA-marked product information

[0713] Chemical information

[0714] Function / role

[0715] Indications and contraindications

[0716] ·Test studies, side effects, warnings Example

[0717] Example 1. Preparation of linker-effector reagents for antibody binding

[0718] The following solvents, reagents, protecting groups, moieties and other names may be referred to by abbreviations in parentheses.

[0719]

[0720]

[0721] Synthesis of AN-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-11-(3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-((((S)-8-methoxy-6-oxo-12a,13-dihydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)-13,13-dimethyl-2,5,8-trioxa-14,15-dithia-11-azanonadecan-19-amide, Compound D6

[0722]

[0723] To a solution of free thiol 6a (40 mg, 0.042 mmol) and NHS4-(2-pyridyldithio)butyrate (35 mg, 80% purity, 0.085 mmol) in anhydrous dichloromethane (0.5 mL) was added anhydrous diisopropylethylamine (0.015 mL, 0.085 mmol) and stirred at room temperature for 16 hours. The reaction mixture was quenched with saturated ammonium chloride and diluted with dichloromethane. The obtained mixture was separated in a separatory funnel. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and stripped under reduced pressure. The residue was purified by semi-preparative reverse phase HPLC (C18 column, CH3CN / H2O). The fractions containing the pure product were combined, frozen and lyophilized to give the desired NHS ester, 6b (29.7 mg, 60% yield). LCMS = 9.1 min (15 min method). MS (m / z): 1157.3 (M+1) + .

[0724]

[0725] To a solution of NHS ester, 6b (12.3 mg, 0.011 mmol) and N-(2-aminoethyl)maleimide hydrochloride (2.0 mg, 0.011 mmol) in anhydrous dichloromethane (0.3 mL) was added DIPEA (0.0022 mL, 0.013 mmol). The mixture was stirred at room temperature for 3 hours and then it was stripped under reduced pressure. The residue was purified by semi-preparative reverse phase HPLC (C18 column, CH3CN / H2O). The fractions containing the pure product were combined, frozen and lyophilized to give the desired maleimide, Compound D6 (10 mg, 80% yield). LCMS = 8.3 min (15 min method). MS (m / z): 1181.8 (M+1) + .

[0726] B. Synthesis of N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-((((S)-8-methoxy-6-oxo-12a,13-dihydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)ethanediamide, Compound D5

[0727]

[0728] NHS ester 5a (8.2 mg, 7.6 μmol) and 1-(2-aminoethyl)-1H-pyrrole-2,5-dione hydrochloride (2.2 mg, 0.011 mmol) were dissolved in anhydrous dichloromethane (305 μL) at room temperature. DIPEA (2.66 μL, 0.015 mmol) was added and the reaction was stirred for 3.5 hours. The reaction mixture was concentrated and purified by RPHPLC (C18 column, CH3CN / H2o, gradient, 35% to 55%). The desired product fractions were frozen and lyophilized to give the maleimide, compound D5 (5.3 mg, 58% yield) as a solid white powder. LCMS = 5.11 min (8 min method). MS (m / z): 1100.6 (M+1) + .

[0729] C. Synthesis of 1-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-4-((5-((3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-((((S)-8-methoxy-6-oxo-12a,13-dihydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-2-methyl-5-oxopentan-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid, Compound D4

[0730]

[0731] To a suspension of the free thiol, 4a (88 mg, 0.105 mmol) and 1-((2,5-dioxopyrrolidin-1-yl)oxy)-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid (64.0 mg, 0.158 mmol) in anhydrous dichloromethane (2.10 mL) was added DIPEA (55.0 μL, 0.315 mmol) at room temperature under nitrogen. The mixture was stirred for 16 hours and then 1-(2-aminoethyl)-1H-pyrrole-2,5-dione hydrochloride (55.6 mg, 0.315 mmol), anhydrous dichloromethane (1.0 mL) and DIPEA (0.055 mL, 0.315 mmol) were added. The mixture was stirred for another 5 hours at room temperature, after which the reaction was concentrated in vacuo. The resulting residue was purified by RP-HPLC (C18 column, CHCN / H0). Fractions containing the desired product were frozen and lyophilized to give the maleimide, Compound D4 (20 mg, 16% yield) as a white solid. LCMS = 4.92 min (8 min method). MS (m / z): 1158.6 (M+1) + .

[0732] Synthesis of DN-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-11-(3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-((((S)-8-methoxy-6-oxo-12a,13-dihydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)-2,5,8-trioxa-11-azapentadecan-15-amide, Compound D7

[0733]

[0734] To a solution of NHS ester, 7a (5 mg, 4.82 μmol) and 1-(2-aminoethyl)-1H-pyrrole-2,5-dione hydrochloride (1.7 mg, 9.64 μmol) in anhydrous dichloromethane (200 μL) was added DIPEA (1.512 μL, 8.68 μmol) under nitrogen. The mixture was stirred at room temperature for 4 hours and then concentrated in vacuo. The resulting residue was purified by RP-HPLC (C18 column, CH3CN / H2O). The fractions containing the desired product were frozen and lyophilized to give the maleimide, Compound D7 (3.5 mg, 68% yield). LCMS = 4.61 min (15 min method). MS (m / z): 1062.8 (M+1) + .

[0735] Example 2. Antibody Binding to Exemplary Linker-Effector Reagents

[0736] Antibody Reagents

[0737] Using standard molecular cloning procedures, the expression vector encoding the heavy chain of the previously described humanized MOV19 antibody (huMOV19, U.S. Patent No. 8,557,966, incorporated herein by reference) was mutagenized so that the expressed protein contained a cysteine ​​residue at EU / OU numbering position 442 of the heavy chain CH3 domain. Using existing procedures for human IgG1 antibodies, huMOV19-HC-C442 IgG1 variants (or huMOV19-C442 for short) were expressed in mammalian cells and purified from mammalian cells. A similar procedure was used to clone, express, and purify multiple variants of the huCD123-6G antibody carrying the same cysteine ​​442 mutation (e.g., huCD123-6Gv1.1-C442 and huCD123-6Gv4.7-C442). These huCD123-6 antibodies are described in detail in U.S. Provisional Application No. 62 / 186,161, filed on June 29, 2015, entitled “ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF,” the entire contents of which (including all protein and nucleic acid sequences and drawings) are incorporated herein by reference.

[0738] A.huMOV19-C442-Mal-CX1-1-DM1

[0739] The huMOV19-C442 antibody carrying two unpaired cysteine ​​residues in the reduced state (at position C442 in the heavy chain CH3 region) was prepared using standard protein chemistry procedures. To a solution of this intermediate in phosphate buffered saline (PBS), 5mM N,N,N',N'-ethylenediaminetetraacetic acid (EDTA) pH 6.0, N,N-dimethylacetamide (DMA) and 8 molar equivalents of Mal-CX1-1-DM1 (see WO 2014 / 134486) were added as a stock solution in DMA to give a reaction mixture with a final solvent composition of 10% v / v DMA in PBS 5mM EDTA pH 6.0. The reaction was allowed to proceed overnight at 25°C.

[0740]

[0741] After forming a covalent bond between the free thiol group of the C442 residue shown above and the maleimido (Mal) group of Mal-CX1-1-DM1, the conjugate was purified using a Sephadex G25 desalting column into 10 mM succinate, 250 mM glycine, 0.5% sucrose, 0.01% Tween-20 pH 5.5 formulation buffer, concentrated by ultrafiltration through a membrane with a 10 kDa molecular weight cutoff, and filtered through a 0.22 μm syringe filter. The conjugate was then dialyzed with the same buffer using a membrane with a 10 kDa molecular weight cutoff.

[0742] The conjugate was found to have an average of 2 mol DM1 / mol antibody by UV-Vis; 99.3% monomer by SEC; and no detectable unbound DM1 by HPLC on a HISEP column. Figure 1A LC-MS of the deglycosylated conjugate is shown in .

[0743] B.huMOV19-C442-Mal-SPDB-DM4

[0744] The huMOV19 antibody carrying two unpaired cysteine ​​residues in the reduced state (at position C442 in the heavy chain CH3 region) was prepared using standard procedures. To a solution of this intermediate in phosphate buffered saline (PBS), 5 mM N, N, N', N'-ethylenediaminetetraacetic acid (EDTA) pH 6.0, N, N-dimethylacetamide (DMA) and 6 molar equivalents of Mal-SPDB-DM4 (see WO 2014 / 134483) were added as a stock solution in DMA to give a reaction mixture with a final solvent composition of 10% v / v DMA in PBS 5 mM EDTA pH 6.0. The reaction was allowed to proceed overnight at 25°C.

[0745]

[0746] The conjugate was purified using a Sephadex G25 desalting column into a 10 mM succinate, 250 mM glycine, 0.5% sucrose, 0.01% Tween-20 pH 5.5 formulation buffer, concentrated by ultrafiltration through a membrane with a 10 kDa molecular weight cutoff, and filtered through a 0.22 μm syringe filter. The conjugate was then dialyzed with the same buffer using a membrane with a 10 kDa molecular weight cutoff.

[0747] The conjugate was found to have 2 mol DM4 / mol antibody by UV-Vis; 99.5% monomer by SEC; and 0.8% unbound DM4 by HPLC on a HISEP column. Figure 1B LC-MS of the deglycosylated conjugate is shown in .

[0748] C.huMOV19-C442-D5

[0749] The huMOV19 antibody carrying two unpaired cysteine ​​residues in the reduced state (at position C442 of the heavy chain CH3 region) was prepared using standard procedures. To a solution of this intermediate in phosphate buffered saline (PBS), 5 mM N,N,N',N'-ethylenediaminetetraacetic acid (EDTA) pH 6.0, N,N-dimethylacetamide (DMA), propylene glycol and 8 molar equivalents of compound D5 as a stock solution in DMA were added to give a reaction mixture with a final solvent composition of 2% v / v DMA and 38% v / v propylene glycol in PBS 5 mM EDTA pH 6.0. The reaction was allowed to proceed at 25°C for 24 hours.

[0750] The conjugate was purified using a Sephadex G25 desalting column into 20 mM histidine, 50 mM sodium chloride, 8.5% sucrose, 0.01% Tween-20, 50 μM sodium bisulfite pH 6.2 formulation buffer, concentrated by ultrafiltration through a membrane with a 10 kDa molecular weight cutoff, and filtered through a 0.22 μm syringe filter. The conjugate was then dialyzed with the same buffer using a membrane with a 10 kDa molecular weight cutoff.

[0751] The conjugate was found to have an average of 2 mol D5 / mol antibody by UV-Vis; 94.6% monomer by SEC; and 0.8% unbound D5 by SEC / reverse phase HPLC. Figure 1C LC-MS of the deglycosylated conjugate is shown in .

[0752] D.huMOV19-C442-D4

[0753] The huMOV19 antibody carrying two unpaired cysteine ​​residues in the reduced state (at position C442 of the heavy chain CH3 region) was prepared using standard procedures. To a solution of this intermediate in phosphate buffered saline (PBS), 5 mM N,N,N',N'-ethylenediaminetetraacetic acid (EDTA) pH 6.0, N,N-dimethylacetamide (DMA), propylene glycol and 6 molar equivalents of D4 as a stock solution in DMA were added to give a reaction mixture with a final solvent composition of 2% v / v DMA and 38% v / v propylene glycol in PBS 5 mM EDTA pH 6.0. The reaction was allowed to proceed at 25°C for 24 hours.

[0754] The conjugate was purified using a Sephadex G25 desalting column into 20 mM histidine, 50 mM sodium chloride, 8.5% sucrose, 0.01% Tween-20, 50 μM sodium bisulfite pH 6.2 formulation buffer, concentrated by ultrafiltration through a membrane with a 10 kDa molecular weight cutoff, and filtered through a 0.22 μm syringe filter. The conjugate was then dialyzed with the same buffer using a membrane with a 10 kDa molecular weight cutoff.

[0755] The conjugate was found to have an average of 2 mol D4 / mol antibody by UV-Vis; 92.1% monomer by SEC; and 0.3% unbound D4 by SEC / reverse phase HPLC. Figure 1D LC-MS of deglycosylated antibody is shown in .

[0756] E.huCD123-6Gv1.1S2-C442-D7

[0757] The huCD123 antibody carrying two unpaired cysteine ​​residues (at the C442 position in the heavy chain CH3 region) in a reduced state (and an engineered N-terminal Ser on the heavy chain) was prepared using standard procedures. To this intermediate in a solution of phosphate buffered saline (PBS), 5mM N, N, N', N'-ethylenediaminetetraacetic acid (EDTA) pH 6.0, N, N-dimethylacetamide (DMA), propylene glycol, and 10 molar equivalents of compound D7 were added as a stock solution in DMA to obtain a reaction mixture having a final solvent composition of 2% v / v DMA and 38% v / v propylene glycol in PBS 5mM EDTA pH 6.0. The reaction was allowed to proceed at 25°C for 24 hours.

[0758] The conjugate was purified using a Sephadex G25 desalting column into 20 mM histidine, 50 mM sodium chloride, 8.5% sucrose, 0.01% Tween-20, 50 μM sodium bisulfite pH 6.2 formulation buffer, concentrated by ultrafiltration through a membrane with a 10 kDa molecular weight cutoff, and filtered through a 0.22 μm syringe filter. The conjugate was then dialyzed with the same buffer using a membrane with a 10 kDa molecular weight cutoff.

[0759] The conjugate was found to have 2 mol D7 / mol antibody by UV-Vis; 97.2% monomer by SEC; and 1.9% unbound D7 by SEC / reverse phase HPLC. Figure 1E LC-MS of the deglycosylated conjugate is shown in .

[0760] F.huCD123-6Gv4.7-C442-D5 / huCD123-6Gv4.6-C442-D5

[0761] Standard procedures were used to prepare huCD123 antibodies (huCD123-6Gv4.7-C442 or huCD123-6Gv4.6-C442) carrying two unpaired cysteine ​​residues in a reduced state. Both huCD123 antibodies have an engineered Cys residue at EU / OU numbering position 442 in the heavy chain CH3 region, and are only different from the 2nd residue at the end of the heavy chain N- (i.e., Val for huCD123-6Gv4.7-C442; and Phe for huCD123-6Gv4.6-C442).

[0762] To this intermediate in phosphate buffered saline (PBS), 5mM N,N,N',N'-ethylenediaminetetraacetic acid (EDTA) pH 6.0, N,N-dimethylacetamide (DMA), propylene glycol and 10 molar equivalents of compound D5 as a stock solution in DMA were added to give a reaction mixture having a final solvent composition of 2% v / v DMA and 38% v / v propylene glycol in PBS 5mM EDTA pH 6.0. The reaction was allowed to proceed at 25°C for 24 hours.

[0763] The conjugate was purified using a Sephadex G25 desalting column into 20 mM histidine, 50 mM sodium chloride, 8.5% sucrose, 0.01% Tween-20, 50 μM sodium bisulfite pH 6.2 formulation buffer, concentrated by ultrafiltration through a membrane with a 10 kDa molecular weight cutoff, and filtered through a 0.22 μm syringe filter. The conjugate was then dialyzed with the same buffer using a membrane with a 10 kDa molecular weight cutoff.

[0764] The conjugate was found to have an average of 2 mol D5 / mol antibody by UV-Vis; and 94.8% monomer by SEC. Figure 1F LC-MS of the deglycosylated conjugate is shown in .

[0765] G.huCD123-6Gv4.7-C442-D4 / huCD123-6Gv4.6-C442-D4

[0766] The huCD123 antibodies carrying two unpaired cysteine ​​residues in the reduced state (huCD123-6Gv4.7-C442 and huCD123-6Gv4.6-C442, see above) were prepared using standard procedures.

[0767] To this intermediate in phosphate buffered saline (PBS), 5 mM N, N, N', N'-ethylenediaminetetraacetic acid (EDTA) pH 6.0, N, N-dimethylacetamide (DMA), propylene glycol and 5 molar equivalents of compound D4 as a stock solution in DMA were added to give a reaction mixture having a final solvent composition of 2% v / v DMA and 38% v / v propylene glycol in PBS 5 mM EDTA pH 6.0. The reaction was allowed to proceed at 25° C. for 6 hours.

[0768] The conjugate was purified using a Sephadex G25 desalting column into 20 mM histidine, 50 mM sodium chloride, 8.5% sucrose, 0.01% Tween-20, 50 μM sodium bisulfite pH 6.2 formulation buffer, concentrated by ultrafiltration through a membrane with a 10 kDa molecular weight cutoff, and filtered through a 0.22 μm syringe filter. The conjugate was then dialyzed with the same buffer using a membrane with a 10 kDa molecular weight cutoff.

[0769] The conjugate was found to have 1.8 mol D4 / mol antibody by UV-Vis; and 97.4% monomer by SEC. Figure 1G LC-MS of the deglycosylated conjugate is shown in .

[0770] Figure 8 It was shown that binding of the huCD123-6Gv4.7 antibody to the D4 and D5 compounds via a Cys-linkage only slightly affected the binding affinity of the conjugates.

[0771] Example 3. In vitro efficacy of huCD123-6Rv1.1-C442-D5 on cells expressing CD123

[0772] An in vitro cytotoxicity assay was used to compare the ability of huCD123-6Rv1.1-C442-D5 to a lysine-linked conjugate (huCD123-6Rv1.1-D2) containing the same antibody and payload to kill cells expressing CD123 on the cell surface.

[0773] For chimeric anti-CD123 antibodies (chCD123), the confirmed variable region amino acid sequences of murine CD123 antibodies were codon optimized, synthesized and cloned in-frame with human antibody constant regions by Blue Heron Biotechnology to construct chimeric versions of CD123 antibodies using human IgG1 and kappa constant sequences for heavy and light chains, respectively.

[0774] The cell line is cultured in the culture medium as suggested by the cell supplier (ATCC or DSMZ). 2,000 to 10,000 cells in 100 μL culture medium are added to each well of a flat-bottomed 96-well plate. To block the Fc receptors on the cell surface, the culture medium is supplemented with 100 nM chKTI antibody (antibody of the same isotype). The conjugate is diluted into the culture medium using a 3-fold dilution series, and 100 μL is added to each well. To determine the contribution of CD123-independent cytotoxicity, CD123 blocking antibodies (100 nM chCD123-6 antibodies) are added to some wells before adding the test conjugate. In each analysis plate, negative control wells containing cells and culture medium but lacking conjugates and wells containing only culture medium are included. Analyzed in triplicate for each data point. The plate is incubated in a humidified 6% CO2 incubator at 37°C for 4 to 7 days. Then use the cell counting kit-8 (Dojindo Molecular Technologies, Inc., Rockville, MD) based on WST-8 to measure the relative number of living cells in each hole.By first correcting for the culture medium background absorbance and then calculating the apparent cell survival score in each hole by the mean value of the value in the control wells (untreated cells).The cell survival score is plotted into a semi-logarithmic curve for the binding substance concentration.

[0775] The data showed that the huCD123-6Rv1.1-C442-D5 conjugate was at least as active as the lysine-linked huCD123-6Rv1.1-D2 conjugate against a variety of cell lines. Figure 2 Several examples of cytotoxicity analysis using the AML cell line EOL-1, the B-ALL cell line KOPN-8, and the CML cell line MOLM-1 are shown in .

[0776] Both conjugates killed cells in a dose-dependent manner, with IC 50The values ​​were approximately 0.002 nM, 0.005 nM and 0.02 nM, respectively. Killing was CD123 dependent, as the conjugate was at least 100-fold less toxic to the cells when the CD123 antigen was blocked by unconjugated chCD123-6 antibody.

[0777] Example 3a In vitro efficacy of huCD123-6Rv1.1-C442-D5' on cells expressing CD123

[0778] huCD123 conjugates of D5' (a DNA cross-linking agent) were prepared according to a similar procedure as described in Example 2. The resulting conjugates were tested for in vitro potency against various AML progenitor cells. Median IC 50 The values ​​are in the picomolar range.

[0779] Example 4. huMOV19-C442 binder to FRα + In vitro potency of cell lines

[0780] An in vitro cytotoxicity assay was used to compare the ability of huMOV19-C442-D5 and huMOV19-C442-D4 to lysine-linked conjugates (huMOV19-D2 and huMOV19-sulfo-SPDB-D1) containing the same antibody and payload to kill cells expressing folate receptor alpha (FRα) on the cell surface. The cell lines were cultured in culture medium as recommended by the cell supplier (ATCC or DSMZ). 1,000-2,000 cells in 100 μL of culture medium were added to each well of a flat-bottom 96-well plate. The conjugate was diluted into culture medium using a 3-fold dilution series, and 100 μL was added to each well. To determine the contribution of FRα-independent cytotoxicity, cells in some wells were incubated with 2 μM huMOV19 antibody before adding the conjugate ("blocking" or "+B"). Control wells containing cells and culture medium but lacking conjugates and wells containing culture medium alone were included in each assay plate. Analyze in triplicate for each data point. Plates were incubated at 37°C in a humidified 6% CO2 incubator for 5 to 6 days. Then the relative number of viable cells in each well was determined using either the Alamar Blue reagent according to the manufacturer's protocol (Life Technologies) or the cell counting kit-8 (Dojindo Molecular Technologies, Inc., Rockville, MD) based on WST-8. The apparent cell survival fraction in each well was calculated by first correcting for the culture medium background absorbance and then dividing each value by the mean value of the value in the control wells (untreated cells). The cell survival fraction was plotted into a semi-logarithmic curve for the conjugate concentration.

[0781] The Cys-linked huMOV19-C442-D5 conjugate was at least as active as the Lys-linked huMOV19-D2 conjugate against a variety of cell lines. Figure 3A and 3B Two examples of cytotoxicity assays using the cervical cancer KB cell line and the metastatic breast cancer T47D cell line are shown in FIG. Both conjugates killed cells in a dose-dependent manner, with the IC 50 Values ​​were approximately 0.007-0.01 nM, and 0.01-0.02 nM for T47D (on a molar antibody basis). Killing was FRα-dependent, as the conjugate was at least 100-fold less toxic to the cells when the FRα antigen was blocked by unbound huMOV19 antibody.

[0782] Similarly, the huMOV19-C442-D4 conjugate was tested on KB cells and found to be at least as active as the lysine-linked huMOV19-sulfo-SPDB-D1 conjugate. Figure 3C An exemplary cytotoxicity assay is shown in . Both conjugates killed cells in a dose-dependent manner, with IC 50 Values ​​were approximately 0.009-0.01 nM. Killing was FRα-dependent, as the conjugate was at least 100-fold less toxic to the cells when the FRα antigen was blocked by unbound huMOV19 antibody.

[0783] Example 5. Bystander Activity

[0784] About 50 μL / well of conjugate (Cys-linked huMOV19-C442-D5 conjugate or Lys-linked huMOV19-D2 conjugate) were each plated at 1×10 in RPMI-1640 (Life Technologies) supplemented with heat-inactivated 10% FBS (Life Technologies), 0.1 mg / mL gentamycin (Life Technologies), and βME (Life Technologies) in a 96-well plate (Falcon, round bottom). -10 M and 4×10 -10M concentration was diluted in six replicates. Two 300.19 cells (mouse) expressing recombinant FOLR1 (FR1#14) or no expression vector (parent) were counted on a hemocytometer. 1000 FR1#14 cells per well at 50 μL / mL were added to wells containing conjugates or culture medium only, 2000 parent cells per well at 50 μL / mL were added to wells containing conjugates or culture medium only, and FR1#14 and parent cells were added together to wells containing conjugates or culture medium only. All plates were incubated in a 37°C incubator with 5% CO2 for 4 days. The total volume was 150 μL per well. After incubation, cell viability was analyzed by adding 75 μL Cell Titer Glo (Promega) per well and developing it for 30 minutes. Luminescence was read on a photometer and the background in the wells containing only culture medium was deducted from all values. A bar graph of the mean value of each cell treatment was drawn using Graph Pad Prism.

[0785] As in Figure 4A and 4B As shown in , the Cys-linked huMOV19-C442-D5 conjugate and the Lys-linked huMOV19-D2 conjugate showed efficient bystander killing of neighboring antigen-negative cells.

[0786] Example 6. In vivo efficacy of huMOV19-C442-D5 in the NCI-H2110 mouse xenograft model

[0787] The antitumor activity of huMOV19-C442-D5 was evaluated in an established subcutaneous xenograft model of non-small cell lung cancer (NSCLC).

[0788] SCID mice (24 animals) were injected subcutaneously into the right flank of the mice with NCI-H2110 human NSCLC cells (1×10 7 When the tumor reached about 100 mm 3 At 4 dpi (6 days after tumor cell inoculation), mice were randomized into treatment groups of 6 animals each based on tumor volume and treated with a single intravenous injection of huMOV19-D2 or huMOV19-C442-D5, two doses each, according to the table below.

[0789] 1. Vehicle Control

[0790] 2. huMOV19-D2 (Lys-linked) 2.7 μg / kg intravenous, single dose

[0791] 3. huMOV19-D2 (Lys-linked) 8.9 μg / kg intravenous, single dose

[0792] 4. huMOV19-C442-D5 2.6 μg / kg intravenous, single dose

[0793] 5. huMOV19-C442-D5 8.7 μg / kg intravenous, single dose

[0794] Doses were given based on D2 or D5 concentrations. At higher doses, all ADCs were highly active to the same degree against NCI-H2110 xenografts (mean T / C = 1%-2% on day 22), with complete regression in 6 of 6 animals. At lower doses, both ADCs were active to a similar degree, with huMOV19-D2 producing a mean T / C = 32% (day 22) and huMOV19-C442-D5 producing a mean T / C = 39% (day 22).

[0795] See the results summarized in the table below. See also Figure 5 .

[0796]

[0797] The results demonstrate that all binders tested were similarly active in the NCI-H2110 NSCLC xenograft model, regardless of binder type or binding site.

[0798] Example 7. Pharmacokinetics of huMOV19-C442-D5 in mice

[0799] The pharmacokinetics of huMOV19-C442-D5 were evaluated in female CD1 mice. Female CD1 mice (9 animals) aged approximately 7 weeks received a single intravenous injection of 2.5 mg / kg huMOV19-C442-D5. Blood was then collected from the retroorbital sinus at the following time points: 2 and 30 minutes; 2, 4 and 8 hours; 1, 2, 3, 5, 7, 10, 14, 21 and 28 days. Samples were collected in a rotating manner, with n=3 animals per time point, and no more than two animal samples were taken within 24 hours. The blood samples were centrifuged and the plasma was decanted into polypropylene tubes and then stored at -80°C until analysis.

[0800] The plasma concentration of huMOV19 antibody was determined using an ELISA assay using a plate coated with goat anti-human IgG for capture and an anti-human IgG Fc connected to horseradish peroxidase for detection. The quantitative limit of the assay was 1.6 ng / mL. The plasma concentration of D5 connected to human IgG was determined using an ELISA assay using a plate coated with anti-indoline and benzodiazepine compound antibodies, and detected using the same anti-human IgG Fc / horseradish peroxidase reagent as used for the above-mentioned antibody assay. The LOQ for this assay was 1.0 ng / mL. For each time point, the average plasma concentration of each of the three individual animal samples was reported.

[0801] like Figure 6 As shown in , the conjugate has a pharmacokinetic profile similar to that of the unconjugated antibody.

[0802] Example 8. Acute tolerance of a single dose of huMOV19-C442-D5 in female CD-1 mice

[0803] Seven-week-old female CD-1 mice were received from Charles River Laboratory. Mice were housed for an acclimatization period of at least 7 days after arrival before the start of the study. Two mice per group were used, based on a D5 concentration of 175 μg / kg ( Fig. 7A ) or 218 μg / kg ( Figure 7B )huMOV19-C442-D5 dose to determine the appropriate dose for the full MTD study.

[0804] For the MTD study, animals were randomly divided into groups (n=8) based on body weight. Mice received a single intravenous administration of vehicle control (0.1 mL / mouse) or 153, 175 or 218 μg / kg huMOV19-C442-D5 based on D5 concentration. The drug was administered intravenously with a 1.0 mL syringe equipped with a 27-gauge 1 / 2-inch needle. Body weight was measured daily for at least one week, and then at least twice a week for the remainder of the experiment. The body weight (BW) of mice is expressed as a percentage of the change in body weight before treatment as follows:

[0805] BW change % = [(BW after / BW before) - 1] × 100

[0806] Wherein "BW after" is the weight after treatment, and "BW before" is the starting body weight before treatment.

[0807] The nadir body weight loss (BWL) percentage is expressed as the mean change in body weight after treatment. Animals were killed (1) if the body weight loss exceeded 20% of the initial weight at any point in the study. Mice were also killed if (2) one or both hind limbs became paralyzed or if (3) the animal was too unwell to access food and water.

[0808]

Claims

1. An antibody-cytotoxic agent conjugate, wherein the antibody-cytotoxic agent conjugate is represented by the following formula: or a pharmaceutically acceptable salt thereof, in: (i) Ab is an antibody having a cysteine ​​residue, and is covalently linked to the linking moiety J via the thiol group S of the cysteine ​​residue CB '; (ii)J CB 'for wherein s1 is a site covalently linked to the cysteine ​​residue, and s2 is a site covalently linked to the group L; (iii) -L- is represented by the following structural formula: in: S3 is covalently linked to J CB ', and s4 is a site covalently linked to D; R 23 and R 24 is H; m' is an integer between 1 and 6; and R h’ is H; (iv) D is a cytotoxic agent covalently linked to a linker L, which is covalently linked to J CB ', wherein D is represented by the following structural formula: in: L" and L"' are both H; and L' is represented by the following formula: -NR 5 -P 1 -C(=O)-(CR a R b ) s -C(═O)-(B1′); or -NR 5 -P 1 -C(=O)-Cy-(CR a R b ) s1’ -C(=O)-(B2’); R 5 is –H; P 1 A peptide containing 2 to 5 amino acid residues; R a and R b Each occurrence is independently -H, (C 1 -C 3 ) alkyl or group Q, group Q is -SO 3 H or a pharmaceutically acceptable salt thereof; s is an integer from 1 to 6; s1' is 0 or an integer from 1 to 6; and Cy is cyclohexane; G is –CH-; Double line between N and C represents a single bond or a double bond, with the restriction that when it is a double bond, X 1 does not exist and Y 1 is -H; and when it is a single bond, X 1 For -H and Y 1 -OH or -SO 3 M; R 1 , R 2 , R 3 , R 4 , R 1 '、R 2 '、R 3 ' and R 4 'All -H; R 6 is -OMe; X 1 ' and Y 1 'All -H; A and A' are -O-; and M is H + 、Na + or K + ;and (v)w is 1 or 2.

2. The conjugate of claim 1, wherein the cysteine ​​residue is recombinantly introduced into the Ab.

3. The conjugate according to claim 1, wherein -J CB '-L- is represented by the following structural formula:

4. The conjugate according to claim 1, wherein R a With R b Both are H. The conjugate according to claim 1 , wherein s1′ is 0 or 1.

6. The conjugate according to claim 1, wherein P 1 Gly-Gly-Gly, Ala-Val, Val-Ala, Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Trp, Cit, Phe-Ala, Phe-N 9 -Tosyl-Arg, Phe-N 9 - Nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala-Leu (SEQ ID NO: 14), β-Ala-Leu-Ala-Leu (SEQ ID NO:15), Gly-Phe-Leu-Gly (SEQ ID NO:16), Val-Arg, Arg-Val, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val- D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-Ala, D-Ala-D-Ala, Ala-Met or Met-Ala.

7. The conjugate according to claim 6, wherein P 1 It is Gly-Gly-Gly, Ala-Val, Ala-Ala, Ala-D-Ala, D-Ala-Ala or D-Ala-D-Ala.

8. The conjugate of claim 1, wherein the doublet between N and C Represents a double bond.

9. The conjugate according to claim 1, wherein D is represented by the following structural formula:

10. The conjugate according to claim 1, wherein the conjugate is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

11. The conjugate according to any one of claims 1 to 10, wherein w is 2. 12 . A pharmaceutical composition comprising the conjugate according to claim 1 and a pharmaceutically acceptable carrier.

13. Use of a conjugate as claimed in any one of claims 1 to 11 in the preparation of a medicament for inhibiting abnormal cell growth or treating cancer in a mammal, optionally in combination with a second therapeutic agent.

14. The use according to claim 13, wherein the cancer is a hematological cancer or a solid tumor.

15. The use according to claim 14, wherein the hematological cancer is leukemia or lymphoma.

16. The use according to claim 14, wherein the solid tumor is melanoma, lung cancer, ovarian cancer, endometrial cancer, peritoneal cancer, pancreatic cancer, breast cancer, prostate cancer or cervical cancer.

17. The use according to claim 15, wherein the hematological cancer is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL).

18. The use according to claim 15, wherein the hematological cancer is B-acute lymphoblastic leukemia (B-ALL).

19. The use according to claim 16, wherein the solid tumor is non-small cell lung cancer.

Citation Information

Patent Citations

  • Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates

    US20050169933A1

  • Antibodies and immunoconjugates and uses therefor

    US20080050310A1

  • Antibody-drug conjugates and methods

    US20080171040A1

  • Engineered Antibodies and Immunoconjugates

    US20080305044A1

  • Cross-linkers and their uses

    US20090274713A1